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Abstract
Background Oral contraceptive pills (OCPs) are double agents, which downregulate endogenous concentrations of oestradiol 
and progesterone whilst simultaneously providing daily supplementation of exogenous oestrogen and progestin during the 
OCP-taking days. This altered hormonal milieu differs significantly from that of eumenorrheic women and might impact 
exercise performance, due to changes in ovarian hormone-mediated physiological processes.
Objective To explore the effects of OCPs on exercise performance in women and to provide evidence-based performance 
recommendations to users.
Methods This review complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 
A between-group analysis was performed, wherein performance of OCP users was compared with naturally menstruating 
women, and a within-group analysis was conducted, wherein performance during OCP consumption was compared with 
OCP withdrawal. For the between-group analysis, women were phase matched in two ways: (1) OCP withdrawal versus the 
early follicular phase of the menstrual cycle and (2) OCP consumption versus all phases of the menstrual cycle except for 
the early follicular phase. Study quality was assessed using a modified Downs and Black Checklist and a strategy based on 
the recommendations of the Grading of Recommendations Assessment Development and Evaluation working group. All 
meta-analyses were conducted within a Bayesian framework to facilitate probabilistic interpretations.
Results 42 studies and 590 participants were included. Most studies (83%) were graded as moderate, low or very low quality, 
with 17% achieving high quality. For the between-group meta-analysis comparing OCP users with naturally menstruating 
women, posterior estimates of the pooled effect were used to calculate the probability of at least a small effect (d ≥ 0.2). 
Across the two between-group comparison methods, the probability of a small effect on performance favouring habitual 
OCP users was effectually zero (p < 0.001). In contrast, the probability of a small effect on performance favouring naturally 
menstruating women was moderate under comparison method (1) (d ≥ 0.2; p = 0.40) and small under comparison method (2) 
(d ≥ 0.2; p = 0.19). Relatively large between-study variance was identified for both between-group comparisons ( 휏0.5 = 0.16 
[95% credible interval (CrI) 0.01–0.44] and 휏0.5 = 0.22 [95% CrI 0.06–0.45]). For the within-group analysis comparing OCP 
consumption with withdrawal, posterior estimates of the pooled effect size identified almost zero probability of a small effect 
on performance in either direction (d ≥ 0.2; p ≤ 0.001).
Conclusions OCP use might result in slightly inferior exercise performance on average when compared to naturally menstru-
ating women, although any group-level effect is most likely to be trivial. Practically, as effects tended to be trivial and vari-
able across studies, the current evidence does not warrant general guidance on OCP use compared with non-use. Therefore, 
when exercise performance is a priority, an individualised approach might be more appropriate. The analysis also indicated 
that exercise performance was consistent across the OCP cycle.
Joint first authors: Kirsty J. Elliott-Sale and Kelly L. McNulty.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 9-020-01317 -5) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
1 Introduction
Sex hormones are one of the main determinants of biological 
sex [1]. During adulthood, levels of testosterone, the pre-
dominant male sex hormone, remain consistent in men [2], 
whilst concentrations of oestrogen and progesterone, the pre-
vailing female sex hormones, undergo circamensal changes 
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Key Points 
When compared with a natural menstrual cycle, oral 
contraceptive pill (OCP) use might result in slightly 
inferior exercise performance, although any group level 
effect is most likely to be trivial, and as such from a 
practical perspective, the current evidence does not 
warrant general guidance on OCP use compared with 
non-use.
Exercise performance appeared relatively consistent 
across the OCP cycle, suggesting that different guidance 
is not warranted for OCP-taking days versus non-OCP 
taking days.
In the case of sportswomen who are focussing on 
performance, it is recommended that an individualised 
approach is sought, based on each athlete’s response to 
OCP use.
in women [3], marking one of the major differences between 
sexes. Moreover, the eumenorrheic menstrual cycle is sus-
ceptible to internal (e.g., amenorrhea, oligomenorrhea and 
menorrhagia) and external (e.g., hormonal contraceptives) 
perturbations, highlighting the diversity in ovarian hormone 
profiles between women. In a recent audit of 430 elite female 
athletes, Martin et al. [4] showed that 213 athletes were hor-
monal contraceptive users, meaning that almost half of the 
population surveyed did not have a eumenorrheic menstrual 
cycle. Of these, 145 (68%) athletes reported taking oral con-
traceptive pills (OCPs), making them the most common type 
of hormonal contraceptive used and the second most com-
mon hormonal profile, after non-hormonal contraceptive 
users. These differences in endocrine profiles, between men 
and women, and amongst women (i.e., hormonal contracep-
tive users and non-users), highlight the need for sex-specific 
consideration within sport and exercise science.
Combined OCPs significantly reduce endogenous con-
centrations of 17 beta oestradiol and progesterone [5], when 
compared to the mid-luteal phase of the menstrual cycle, 
a stage when endogenous oestradiol and progesterone are 
relatively high. The exogenous oestrogens and progestins 
act via negative feedback on the gonadotrophic hormones, 
resulting in the chronic downregulation of the hypothalamic-
pituitary-ovarian axis. Most combined, monophasic OCPs 
are second generation OCPs, containing low to standard 
doses of ethinyl oestradiol and either levonorgestrel, nore-
thisterone, desogestrel or gestodene, delivered in a fixed 
amount every day for 21 OCP taking days (i.e., consump-
tion phase), followed by 7 OCP free days (i.e., withdrawal 
phase) [6]. In some countries, rather than a consumption 
and withdrawal approach, there are 21 active OCP days and 
7 inactive OCP days. There are many types of OCPs with 
different compositions and potencies; for a comprehensive 
overview of hormonal contraceptives and OCPs please see 
Elliott-Sale and Hicks [6]. Overall, OCP use results in four 
distinct hormonal environments: (1) a downregulated endog-
enous oestradiol profile of ≈ 60 pmol·L−1 for 21 days that 
rises during the 7 OCP free days to ≈ 140 pmol·L−1; (2) a 
chronically downregulated endogenous progesterone profile 
of ≈ 5 nmol·L−1; (3) a daily surge of synthetic oestrogen and 
progestin that peaks within 1 h after ingestion [from ≈ 2 to 
≈ 6 pg·mL−1], with baseline values accumulating slightly 
from ≈ 2 to ≈ 3 pg·mL−1 over the 21 OCP-taking days; (4) 7 
exogenous hormone-free days [7]. These profiles, reflecting 
OCP consumption and withdrawal, are referred to as pseudo-
phases, as they are “artificial” phases in comparison with the 
phases of the physiological menstrual cycle.
Aside from fertility control, OCPs are also used to alle-
viate the symptoms of dysmenorrhoea and menorrhagia; 
reduce the occurrence of premenstrual tension, symptomatic 
fibroids, functional ovarian cysts and benign breast disease; 
and decrease the risk of ovarian and endometrial cancer and 
pelvic inflammatory disease [8]. Furthermore, athletic popu-
lations have reported strategically using OCPs to manipulate 
the timing of, or omit entirely, the often-perceived incon-
venient withdrawal bleed that occurs during the 7 OCP free 
days, using back-to-back OCP cycles [4, 9, 10]. Reliable and 
reversible contraception, along with the means to alleviate 
the side-effects associated with the eumenorrheic menstrual 
cycle, such as cramps/pain, bloating and headaches, and the 
ability to eliminate unpredictable menstruation, make OCPs 
a desirable option for many athletes.
Despite the prevalence of OCP use in athletic popula-
tions [4], the effects of OCPs on exercise performance are 
poorly understood. Although many experimental studies 
[11–13], numerous narrative and systematic reviews [14, 
15] and books [16, 17] have addressed this topic, few 
in the area of sport and exercise science (e.g., athletes, 
coaches, practitioners or researchers) truly understand 
the implications of OCP use on exercise performance, as 
previous research has shown conflicting findings on the 
directional effects of OCPs on outcomes such as muscle 
function [18, 19], aerobic and anaerobic [20–22] capacity 
and performance-based tests [23, 24]. As such, it is not 
possible to provide useful guidance to either the sport-
ing or research community on how to work with athletes 
or participants using OCPs. Accordingly, the aim of this 
review was to investigate the effects of OCP use on exer-
cise performance in women by making a between group 
comparison of OCP users and non-users (i.e., naturally 
menstruating counterparts) and a within group compar-
ison of OCP consumption and withdrawal. This is the 
first meta-analysis on the effects of OCPs on exercise 
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performance. Additionally, this review is the first of its 
kind to appraise the quality of previous studies using 
robust assurance tools.
2  Methods
2.1  Design
The review was designed in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA; Electronic Supplementary Material 
Appendix S1) guidelines [25], and consideration of the 
Population, Intervention, Comparator, Outcomes and 
Study design (PICOS, Table 1) was used to determine 
the parameters within which the review was conducted. 
2.2  Study Search and Selection
PubMed, The Cochrane Central Register of Controlled Tri-
als (CENTRAL), ProQuest and SPORTDiscus were system-
atically searched using the search terms “oral contracep-
tives” AND “athletic performance”; “sports performance”; 
“muscle”; “skeletal muscle”; “strength”; “force”; “mus-
cular strength”; “muscular force”; “power”; “anaerobic”; 
“anaerobic power”; “anaerobic performance”; “anaerobic 
capacity”; “aerobic”; “aerobic capacity”; “aerobic power”; 
“aerobic performance”; “endurance”; “endurance capacity”; 
“endurance power”; “endurance performance”; “fatigue”; 
“recovery”. Searches were limited to humans, English, and 
females and no date restriction was applied. Only original 
research articles were considered for inclusion and review 
articles or conference abstracts were excluded. An example 
electronic search strategy for PubMed, including limits, can 
be found in Electronic Supplementary Material Appendix 
S2. All searches were conducted in January 2019 by KES. 
Three independent reviewers (KES, KLM and KMH) under-
took a three-phase screening strategy: title and abstract, full-
text screen and full-text appraisal. The search was updated 
in April 2020 using the same search criteria and screening 
strategy. These papers were subsequently included within 
the review and the meta-analysis was updated.
2.3  Data Extraction and Quality Appraisal
Data were extracted by ED using a pre-piloted extraction 
sheet. When data were presented in graphical, and not in 
numerical format, DigitizeIt software (Version 2.3, Digi-
tizeIt, Germany) was used to convert the data. The quality 
of each review outcome (defined as each of the statistical 
models undertaken) was assigned using a strategy based 
on the recommendations of the Grading of Recommenda-
tions Assessment Development and Evaluation (GRADE) 
working group [26]. This approach considers the quality 
of research outcomes in a systematic review according to 
five domains, namely risk of bias, directness, consistency, 
precision and evidence of publication bias. Risk of bias 
and directness were assessed at the individual study level 
with mode ratings used to categorise whole outcomes. The 
meta-analysis results were subsequently used to ascertain 
the consistency, precision and risk of publication bias for 
Table 1  Population, intervention, comparator, outcomes and study design (PICOS) criteria
OCP oral contraceptive pill
Population Healthy women aged 18–40 years were considered for inclusion in this study. No restrictions on activity level or training status 
were placed
Intervention All participants were required to take an OCP, either habitually or experimentally. “Habitual” was defined as OCP use prior to 
the commencement of the study and not for the purposes of the study. “Experimentally” was defined as starting OCP use for 
the purposes of the study. All forms of OCPs were considered for use within this review
Comparator Four broad types of comparisons were considered: (1) Between group comparison of habitual OCP users to naturally menstruat-
ing women. Women were phase matched in two ways for this comparison: (i) OCP withdrawal versus the early follicular phase 
of the menstrual cycle and (ii) OCP consumption versus all other phases of the menstrual cycle except for the early follicular 
phase; (2) within group comparison of OCP consumption with the hormone-free withdrawal phase; (3) comparison of active 
OCP use with non-use (e.g ., within-group comparison of women who were habitual users or non-users who stopped/started 
taking OCP for the purpose of the study); (4) randomised controlled trials of OCPs versus placebo intake ( e.g ., between 
group comparison of naturally menstruating women who were randomly assigned to either an OCP or placebo pill)
Outcomes The primary outcome was to determine any differences in exercise performance, based on the comparisons described above. 
‘Exercise performance’ referred to outcomes stemming from: workload, time to completion and exhaustion, mean, peak out-
puts, rate of production and decline and maximum oxygen uptake (a full list of considered outcomes can be found in Table 2). 
Although maximum oxygen uptake is not a performance test, this physiology-based outcome was included as it is widely used 
as an indicator of performance and is often used to describe the fitness of participants. Different exercise outcomes, broadly 
categorised as endurance and strength were considered. All exercise outcomes were extracted, and effect size duplication of 
multiple outcomes from the same test accounted for within the statistical analysis, as described in Sect. 2.4
Study design Any study design that included the information described above was considered for inclusion
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each outcome. Each individual study was initially appraised 
using a modified version of the Downs and Black Checklist 
[27], which was specifically tailored for use in this review 
(see Electronic Supplementary Material Appendix S3). 
The modified quality appraisal checklist comprised 15 out-
comes, and had a maximum attainable score of 16, with 
all studies classified as being of high (H; 14–16), moder-
ate (M; 10–13), low (L; 6–9) or very low (VL; 0–5) qual-
ity. The results of this assessment were used to assign an a 
priori quality rating to each outcome. This a priori rating 
was either maintained, or downgraded a level, based on the 
response to two questions that were considered key to the 
directness of the research design, i.e., Question 1: was the 
natural menstrual cycle phase confirmed using appropriate 
biochemical outcomes? Question 2: was the type of OCP 
described to the level of detail required for categorisation 
or replication? With regards to Question 1, for studies with 
OCP groups only, biochemical confirmation was not deemed 
necessary, as OCP users do not have cyclical fluctuations in 
endogenous sex hormones, in which case the a priori score 
was maintained rather than downgraded. This rating was 
then either maintained, or downgraded another level based 
on whether the results obtained were consistent (determined 
by visual inspection of effect size estimates and the degree 
of credible intervals [CrI] overlap); precise (with outcomes 
downgraded if they were based on < 5 data points) and 
whether or not publication bias was evidence (determined 
using Egger’s test along with visual inspection of funnel 
plots as described in Sect. 2.4). The proportion of studies 
in each category was reported, with the mode considered to 
represent the overall quality rating for each individual review 
outcome. Two independent reviewers (KES and KMH) veri-
fied the data extraction and quality appraisal.
2.4  Data Analysis
Data were extracted from studies comprising both between 
group and within group designs. Pairwise effect sizes were 
calculated by dividing mean differences by pooled standard 
deviations. At the study level, variance of effect sizes were 
calculated according to standard distributional assumptions 
[28]. All meta-analyses were conducted within a Bayes-
ian framework enabling the results to be interpreted more 
intuitively compared to a standard frequentist approach 
through use of subjective probabilities [29]. With a Bayes-
ian framework, dichotomous interpretations of the results 
of a meta-analysis with regards to the presence or absence 
of an effect (e.g., with p values) can be avoided, and greater 
emphasis placed on describing the most likely values for the 
average effect and addressing practical questions such as the 
probability the average effect is beyond a certain threshold 
[29]. The Bayesian framework is also particularly suited 
to hierarchical models and sharing information within and 
across studies to improve estimates [29]. In the present meta-
analysis, three-level hierarchical models were conducted to 
account for covariance in multiple outcomes presented in 
the same study [30]. Initial models were conducted includ-
ing both strength and endurance outcomes with a regression 
coefficient assessing difference in the average effects. Where 
no evidence of a difference was identified, the model was 
re-run combining both categories of outcomes to increase 
data to better estimate model parameters. Given the expec-
tation of relatively small effect sizes, an a priori threshold 
of ± 2 was identified for outliers. Primary analyses were 
completed with outliers removed but results also presented 
from the full complement of studies as sensitivity analyses. 
Additionally, sensitivity analyses were conducted on data 
obtained from studies categorised as “high” or “moderate” 
in quality. Inferences from all analyses were performed on 
posterior samples generated by Hamiltonian Markov Chain 
Monte Carlo with Bayesian 95% CrIs constructed to enable 
probabilistic interpretations of parameter values [29]. Inter-
pretations were based on visual inspection of the posterior 
sample, the median value  (ES0.5: 0.5-quantile) and 95% CrIs. 
Cohen’s [31] standard threshold value of 0.2 was used to 
describe effect size as small, and values between 0 and 0.2 
were described as trivial. Analyses were performed using the 
R wrapper package brms, which was interfaced with Stan 
to perform sampling [32]. Convergence of parameter esti-
mates was obtained for all models with Gelman–Rubin R-hat 
values below 1.1 [33]. Additional sensitivity analyses were 
conducted by restricting the analysis to studies that included 
exercise performance as the primary study outcome. Assess-
ment of publication bias using Egger’s multilevel test with 
effect sizes regressed on inverse standard errors [34] identi-
fied no evidence of publication bias with median absolute 
intercept values less than 0.1 across all analyses.
2.5  Rationale for Between Group Comparisons
For the between group analyses of habitual OCP users to 
naturally menstruating women, the OCP withdrawal phase 
[days 1–7] was compared with the early follicular phase 
[days 1–5] of the menstrual cycle and the OCP consump-
tion phase [days 8–28] was compared with all phases of 
the menstrual cycle [days 6–28] except the early follicular 
phase [days 1–5]. The OCP withdrawal phase was com-
pared with the early follicular phase as during the with-
drawal phase OCP users experience a withdrawal bleed 
and during the early follicular phase of the menstrual 
cycle women experience menstruation. In addition, dur-
ing both phases endogenous concentrations of oestrogen 
and progesterone are comparably low. During the remain-
der of the menstrual cycle, endogenous concentrations of 
oestrogen and progesterone change over time (e.g., the 
mid-cycle peak in oestrogen and the mid-luteal rise in 
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progesterone and oestrogen) and there is large variation in 
endogenous concentrations of oestrogen and progesterone 
as a result of different OCP formulations. As such, it is 
difficult to make meaningful comparisons during these 
phases and this could be considered a limiting factor of 
any meta-analysis making between group comparisons 
of naturally menstruating women and OCP users. To 
reduce the impact of this limitation, a sensitivity analy-
sis was completed on the between group design data to 
better match the physiological menstrual cycle and OCP 
pseudo-phases. This was achieved by mapping days 1–5, 
12–16 and 19–23 from both cycles, which correspond 
with the early follicular, ovulatory and mid-luteal phases 
in a natural menstrual cycle and represents the following 
hormonal profiles: low oestrogen and progesterone, high 
oestrogen and low progesterone and high progesterone 
and medium oestrogen. As such, this meta-analysis (1) 
compared the two most stable phases of the OCP and 
menstrual cycles in the first between group analyses; (2) 
compared the two least stable phases of the OCP and 
menstrual cycles in the second between group analysis; 
and (3) performed an additional sensitivity analysis to 
better match the OCP and menstrual phases.
3  Results
3.1  Study Characteristics
Figure 1 shows the studies identified and selected by 
the search strategy. Details of the included studies are 
shown in Table 2. In total 42 studies [5, 13, 18–20, 22–24, 
35–68] and 590 participants were included.
Methodological quality at the level of the individual 
study is shown in Fig. 2; 83% of the studies were graded 
as M, L or very low VL, with 17% achieving H quality. 
Specifically, 4 studies were graded as VL, 10 as L, 21 as 
M and 7 as H quality.
3.2  Between Group Analyses of Habitual Oral 
Contraceptive Users Compared to Naturally 
Menstruating Women
Thirty of the included studies (combined quality rating = M; 
specifically 20% H; 37% M; 30% L; 13% VL) generated 
151 effects sizes from research designs comparing habitual 
OCP users with naturally menstruating women. The data 
were collected from 597 participants (habitual OCP n = 303, 
naturally menstruating n = 294) with studies comprising a 
mean group size of 10 (range n = 5–25).
3.2.1  Oral Contraceptive Pill Withdrawal [Days 1–7] Versus 
the Early Follicular Phase [Days 1–5] of the Menstrual 
Cycle
Three outliers were identified with effect sizes greater 
than + 2, and were removed from the analysis, leaving a 
total of 49 effect sizes (26 endurance, 23 strength) from 18 
studies (combined quality rating = M; specifically 17% H; 
33% M; 28% L; 22% VL; habitual OCP n = 176, naturally 
menstruating n = 169). The three-level hierarchical model 
indicated a trivial effect with the median value associating 
greater performances with naturally menstruating women 
 (ES0.5 = 0.18 [95% CrI − 0.02 to 0.37]; Fig. 3). Relatively 
large between-study standard deviation was identified ( 휏
0.5 = 0.16 [95% CrI 0.01–0.44]) with estimates indicating 
moderate intraclass correlation  (ICC0.5 = 0.42 [95% CrI 
0.00–0.80]) due to analysis of multiple outcomes reported 
within studies. Pooling of strength and endurance outcomes 
was conducted as no evidence was obtained that indicated 
a differential effect between the performance categories 
 (ES0.5/Endurance-Strength = 0.04 [95% CrI  − 0.41 to 0.43]). Poste-
rior estimates of the pooled effect size identified a moderate 
probability of a small effect favouring naturally menstruating 
women in the early follicular phase of the menstrual cycle 
(d ≥ 0.2; p = 0.404) and effectually a zero probability favour-
ing habitual OCP women (d ≤  − 0.2; p = 0.001). Inclusion of 
outliers within the model substantially increased the aver-
age effect size  (ES0.5 = 0.34 [95% CrI  − 0.04 to 0.72]) and 
between study variance ( 휏0.5 = 0.70 [95% CrI 0.24–1.23]).
3.2.2  Oral Contraceptive Pill Consumption [Days 8–28] 
Versus all Phases of the Menstrual Cycle [Days 6–28] 
Except the Early Follicular Phase [Days 1–5]
Eleven outliers were identified with effect sizes greater 
than + 2, and were removed from the analysis, leaving a total 
of 88 effect sizes (53 endurance, 35 strength) from 24 stud-
ies (combined quality rating = M; specifically 21% H; 42% 
M; 25% L; 13% VL; habitual OCP n = 244 habitual OCP, 
naturally menstruating n = 230). The three-level hierarchi-
cal model indicated a trivial effect with the median value 
associating greater performances obtained in the naturally 
menstruating women  (ES0.5 = 0.13 [95% CrI  − 0.05 to 0.28]; 
Fig. 4). Relatively large between study variance was identi-
fied 휏0.5 = 0.22 [95% CrI 0.06–0.45] with central estimates 
indicating very low intraclass correlation  ICC0.5 = 0.08 
[95% CrI 0.0–0.61] due to analysis of multiple outcomes 
reported within studies. Pooling of strength and endurance 
outcomes was conducted as no evidence was obtained that 
indicated a differential effect between the performance 
categories  (ES0.5/Endurance-Strength = 0.02 [95% CrI  − 0.25 to 
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id
 
co
nt
ra
ce
pt
ive
, o
r n
o 
co
nt
ra
ce
pt
ive
) o
n 
th
er
m
al,
 m
eta
bo
lic
, 
ca
rd
io
re
sp
ira
to
ry
, 
pe
rfo
rm
an
ce
, b
od
y 
co
m
po
sit
io
n a
nd
 pe
r-
ce
pt
ua
l r
es
po
ns
e o
f 
he
alt
hy
 yo
un
g w
om
en
 
(c
on
tra
ce
pt
ive
) t
o a
 
7–
8 w
ee
k p
ro
gr
am
 of
 
he
at 
ac
cli
m
ati
on
 an
d 
ph
ys
ica
l t
ra
in
in
g
He
alt
hy
 w
om
en
 (2
1 ±
 3 
ye
ar
s) 
wh
o w
er
e n
ot
 
un
de
rta
ki
ng
 fr
eq
ue
nt
 
ph
ys
ica
l t
ra
in
in
g
Pa
ra
lle
l g
ro
up
, i
nt
er-
ve
nt
io
n, 
re
pe
ate
d 
m
ea
su
re
s
Or
al 
eth
iny
l o
es
tra
-
di
ol
 an
d p
ro
ge
sti
n 
co
nt
ra
ce
pt
ive
s 
(O
rth
o-
No
vu
m
, 
Or
th
o-
Cy
cle
n, 
No
rth
i-T
riC
yc
len
, 
M
ar
ve
lo
n o
r F
em
o-
de
ne
)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C,
 te
ste
d 
at 
th
e E
F 
ph
as
e, 
ve
ri-
fie
d b
y s
er
um
 oe
str
o-
ge
n a
nd
 pr
og
es
ter
on
e 
lev
els
̇ V
O 2
 pe
ak
 
(m
l·k
g·m
in
−1
) 
m
ea
su
re
d d
ur
in
g a
n 
in
cr
em
en
tal
 ru
n t
o 
vo
lit
io
na
l f
ati
gu
e—
E
Lo
w
Be
ll 
et 
al.
 [3
7]
To
 m
ea
su
re
 th
e i
nfl
u-
en
ce
 of
 O
CP
 on
 ha
m
-
str
in
g n
eu
ro
m
ec
ha
n-
ics
 an
d l
eg
 st
iff
ne
ss
 
ac
ro
ss
 th
e M
C
He
alt
hy
 w
om
en
 
(2
0.2
 ±
 1.
4 y
ea
rs)
 
wh
o w
er
e p
hy
sic
all
y 
ac
tiv
e (
de
fin
ed
 as
 a 
m
in
im
um
 of
 20
 m
in
 
of
 ac
tiv
ity
 th
re
e t
im
es
 
pe
r w
ee
k)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
M
on
op
ha
sic
 O
CP
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
fo
r t
he
 
pr
ev
io
us
 6 
m
on
th
s, 
tes
ted
 at
 th
e E
F 
an
d 
ov
ul
ati
on
 ph
as
e, 
ve
rifi
ed
 us
in
g u
rin
ar
y 
ov
ul
ati
on
 de
tec
tio
n 
an
d s
er
um
 oe
str
og
en
 
an
d p
ro
ge
ste
ro
ne
 
lev
els
Ra
te 
of
 fo
rc
e p
ro
du
c-
tio
n (
N·
s−
1 ),
 an
d 
tim
e t
o r
ea
ch
 50
% 
pe
ak
 (m
s) 
m
ea
su
re
d 
du
rin
g a
 m
ax
im
al 
vo
lu
nt
ar
y i
so
m
etr
ic 
ha
m
str
in
g c
on
tra
c-
tio
n—
S
M
od
er
ate
Oral Contraceptives and Exercise Performance
Ta
bl
e 
2 
 (c
on
tin
ue
d)
St
ud
y
Ai
m
Pa
rti
cip
an
t h
ea
lth
 an
d 
tra
in
in
g s
tat
us
St
ud
y d
es
ig
n
Or
al 
co
nt
ra
ce
pt
ive
 pi
ll 
ty
pe
Eu
m
en
or
rh
eic
 g
ro
up
 
de
sc
rip
tio
n
Ex
er
cis
e o
ut
co
m
es
Qu
ali
ty
 ra
tin
g
Be
m
be
n e
t a
l. 
[3
8]
To
 m
ea
su
re
 th
e i
nfl
u-
en
ce
 of
 O
CP
 on
 
gr
ow
th
 ho
rm
on
e a
nd
 
pr
ol
ac
tin
 re
sp
on
se
s 
an
d o
n e
ne
rg
y 
su
bs
tra
te 
ut
ili
za
tio
n 
du
rin
g p
ro
lo
ng
ed
 
su
bm
ax
im
al 
ex
er
cis
e
He
alt
hy
, m
od
er
ate
ly
 
ac
tiv
e w
om
en
 
(2
5.1
 ±
 1.
4 y
ea
rs)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
sin
gl
e-
m
ea
su
re
M
ul
ti 
or
 m
on
op
ha
sic
 
OC
Ps
 co
nt
ain
in
g 
35
 µg
 of
 oe
str
og
en
 
(O
rth
o N
ov
um
 10
/1
1, 
7–
7–
7, 
1/
35
 an
d 
De
m
ul
en
)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
(c
yc
les
 
ra
ng
in
g f
ro
m
 28
 to
 
35
 da
ys
 in
 le
ng
th
), 
fo
r o
ne
 ye
ar
 pr
io
r 
to
 th
e s
tu
dy
, t
es
ted
 
at 
th
e E
L,
 M
L 
an
d 
LL
 ph
as
es
, v
er
ifi
ed
 
by
 B
BT
 an
d s
er
um
 
pr
og
es
ter
on
e
̇ V
O 2
 pe
ak
 
(m
l·k
g·m
in
−1
) a
nd
 
ab
so
lu
te 
wo
rk
lo
ad
 
(m
·m
in
−1
) m
ea
su
re
d 
du
rin
g a
n i
nc
re
m
en
-
tal
 ru
n t
o v
ol
iti
on
al 
fat
ig
ue
—
E
Lo
w
Bu
sh
m
an
 et
 al
. [
39
]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 m
en
str
ua
tio
n 
an
d O
CP
 on
 po
we
r 
pe
rfo
rm
an
ce
He
alt
hy
, m
od
er
ate
ly
 
ac
tiv
e w
om
en
 
(2
1.6
 ±
 2.
6 y
ea
rs)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
2 p
ar
tic
ip
an
ts 
to
ok
 a 
m
on
op
ha
sic
 an
d 1
5 a
 
m
ul
tip
ha
sic
 O
CP
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
tes
ted
 
at 
th
e E
F 
an
d E
L 
ph
as
es
, v
er
ifi
ed
 by
 
BB
T 
an
d u
rin
ar
y 
ov
ul
ati
on
 de
tec
tio
n 
tes
t
Es
tim
ate
d 
̇ V
O 2
 pe
ak
 
(m
l·k
g·m
in
−1
) 
m
ea
su
re
d f
ro
m
 
th
e F
or
es
try
 S
tep
 
Te
st—
E;
 pe
ak
 po
we
r 
(W
 or
 W
·kg
−1
), 
an
ae
ro
bi
c c
ap
ac
ity
 
(W
 or
 W
·kg
−1
) a
nd
 
po
we
r d
ec
lin
e (
W
 or
 
W
·kg
−1
) m
ea
su
re
d b
y 
th
e W
in
ga
te 
tes
t—
E 
an
d a
na
er
ob
ic 
po
we
r 
(k
gm
·s−
1 ) 
m
ea
su
re
d 
in
 th
e M
ar
ga
ria
 K
ala
-
m
en
 te
st—
E
Lo
w/
ve
ry
 lo
w
Ca
sa
zz
a e
t a
l. 
[2
0]
To
 m
ea
su
re
 th
e e
ffe
cts
 
of
 M
C 
ph
as
e a
nd
 
tri
ph
as
ic 
OC
P 
us
e 
on
 pe
ak
 ex
er
cis
e 
ca
pa
cit
y
He
alt
hy
, h
ab
itu
all
y 
ac
tiv
e w
om
en
 w
ho
 
we
re
 no
t c
om
pe
tit
ive
 
ath
let
es
 (2
5.5
 ±
 1.
5 
ye
ar
s)
W
ith
in
 g
ro
up
, i
nt
er-
ve
nt
io
n (
OC
P)
, 
re
pe
ate
d m
ea
su
re
s
St
an
da
rd
ize
d t
rip
ha
sic
 
OC
P 
(d
ay
s 1
–7
: 
0.0
35
 m
g e
th
iny
le-
str
ad
io
l a
nd
 0.
18
 m
g 
no
rg
es
tim
ate
; d
ay
s 
8–
14
: 0
.03
5 e
th
iny
le-
str
ad
io
l a
nd
 0.
21
5 
no
rg
es
tim
ate
; d
ay
s 
15
–2
1:
 0.
03
5 m
g 
eth
iny
les
tra
di
ol
 an
d 
0.2
5 m
g n
or
ge
sti
-
m
ate
, d
ay
s 2
2–
28
: 
pl
ac
eb
o p
ill
)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d 
na
tu
ra
l m
on
th
ly
 
M
C 
(2
2–
32
 da
ys
 in
 
len
gt
h)
 fo
r a
t l
ea
st 
6 m
on
th
s, 
tes
ted
 du
r-
in
g t
he
 L
F 
an
d M
L 
ph
as
es
, v
er
ifi
ed
 by
 
a u
rin
ar
y o
vu
lat
io
n 
de
tec
tio
n t
es
t a
nd
 
se
ru
m
 oe
str
og
en
 an
d 
pr
og
es
ter
on
e
Pe
ak
 ̇ V
O 2
 (L
·m
in
−1
), 
po
we
r (
W
) a
nd
 ti
m
e 
to
 ex
ha
us
tio
n (
m
in
) 
m
ea
su
re
d d
ur
in
g a
n 
in
cr
em
en
tal
 cy
cle
 to
 
vo
lit
io
na
l f
ati
gu
e—
E
M
od
er
ate
 K. J. Elliott-Sale et al.
Ta
bl
e 
2 
 (c
on
tin
ue
d)
St
ud
y
Ai
m
Pa
rti
cip
an
t h
ea
lth
 an
d 
tra
in
in
g s
tat
us
St
ud
y d
es
ig
n
Or
al 
co
nt
ra
ce
pt
ive
 pi
ll 
ty
pe
Eu
m
en
or
rh
eic
 g
ro
up
 
de
sc
rip
tio
n
Ex
er
cis
e o
ut
co
m
es
Qu
ali
ty
 ra
tin
g
de
 B
ru
yn
-P
re
vo
st 
et 
al.
 
[4
0]
To
 m
ea
su
re
 th
e 
eff
ec
ts 
of
 O
CP
 an
d 
eu
m
en
or
rh
eic
 M
C 
on
 th
e p
hy
sio
lo
gi
ca
l 
re
sp
on
se
 to
 ae
ro
bi
c 
an
d a
na
er
ob
ic 
en
du
r-
an
ce
 te
sts
W
om
en
 (2
2 ±
 2.
2 
ye
ar
s)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
No
 in
fo
rm
ati
on
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C,
 te
ste
d 
du
rin
g t
he
 E
F,
 ov
ul
a-
to
ry
 an
d L
L 
ph
as
es
, 
ve
rifi
ed
 by
 B
BT
̇ V
O 2
 pe
ak
 (L
·m
in
−1
) 
an
d w
or
ki
ng
 ca
pa
c-
ity
 at
 a 
he
ar
t r
ate
 
of
 17
0 b
pm
 (W
) 
m
ea
su
re
d u
sin
g a
n 
in
cr
em
en
tal
 cy
cle
 to
 
vo
lit
io
na
l f
ati
gu
e—
E,
 
an
d m
ax
im
al 
pe
da
l 
tim
e (
s) 
du
rin
g a
 
fix
ed
 lo
ad
 (3
50
 W
) 
an
ae
ro
bi
c e
nd
ur
an
ce
 
tes
t—
E
Ve
ry
 lo
w
Dr
ak
e e
t a
l. 
[4
1]
To
 m
ea
su
re
 th
e 
eff
ec
t o
f O
CP
 an
d 
eu
m
en
or
rh
eic
 M
C 
on
 el
ec
tro
m
yo
gr
ap
hy
 
an
d m
ec
ha
no
m
yo
gr
a-
ph
y d
ur
in
g i
so
m
etr
ic 
m
us
cle
 co
nt
ra
cti
on
s
He
alt
hy
 w
om
en
 (2
4 ±
 1 
ye
ar
s) 
wh
o w
er
e n
ot
 
inv
ol
ve
d i
n a
n e
xe
r-
cis
e p
ro
gr
am
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
No
 in
fo
rm
ati
on
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d 
na
tu
ra
l m
on
th
ly
 
M
C 
(2
6–
32
 da
ys
 in
 
len
gt
h)
 te
ste
d a
t t
he
 
EF
, L
F,
 ov
ul
ati
on
 an
d 
EL
, v
er
ifi
ed
 us
in
g 
ur
in
ar
y o
vu
lat
io
n 
de
tec
tio
n t
es
t
M
ax
im
al 
an
d s
ub
-
m
ax
im
al 
iso
m
etr
ic 
ex
ten
so
r a
nd
 fl
ex
or
 
co
nt
ra
cti
on
 at
 10
0, 
75
, 5
0 a
nd
 25
% 
of
 
m
ax
im
al 
to
rq
ue
 
(N
 m
)—
S
Ve
ry
 lo
w
Ek
en
ro
s e
t a
l. 
[4
2]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 an
d e
um
en
or
-
rh
eic
 M
C 
on
 m
us
cle
 
str
en
gt
h a
nd
 ho
p 
pe
rfo
rm
an
ce
He
alt
hy
 w
om
en
 
(2
6.7
 ±
 3.
8 y
ea
rs)
 
wh
o w
er
e e
ng
ag
ed
 
in
 m
od
er
ate
 to
 hi
gh
 
lev
els
 of
 re
cr
ea
tio
na
l 
ac
tiv
ity
W
ith
in
-g
ro
up
, i
nt
er-
ve
nt
io
n, 
re
pe
ate
d 
m
ea
su
re
s
Lo
w 
do
se
 m
on
op
ha
sic
 
OC
Ps
 co
nt
ain
in
g 
eth
iny
l o
es
tra
di
ol
 
(2
0–
35
 μ
g)
 co
m
bi
ne
d 
wi
th
 di
ffe
re
nt
 pr
o-
ge
sto
ge
n (
Le
vo
no
rg
-
es
tre
l, 
No
rg
es
tim
ate
, 
Dr
os
pi
re
no
ne
, D
es
-
og
es
tre
l, 
No
re
tis
ter
-
on
e a
nd
 L
yn
es
tre
no
l)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
wh
o 
ha
d n
ot
 be
en
 ta
ki
ng
 
an
y h
or
m
on
e-
co
n-
tai
ni
ng
 co
nt
ra
ce
pt
ive
 
fo
r a
t l
ea
st 
th
re
e 
m
on
th
s p
rio
r t
o t
he
 
stu
dy
, t
es
ted
 du
rin
g 
th
e E
F,
 ov
ul
ato
ry
 an
d 
M
L 
ph
as
es
, v
er
ifi
ed
 
us
in
g u
rin
ar
y o
vu
la-
tio
n d
ete
cti
on
 te
st 
an
d s
er
um
 oe
str
og
en
 
an
d p
ro
ge
ste
ro
ne
Pe
ak
 is
ok
in
eti
c k
ne
e 
ex
ten
so
r s
tre
ng
th
 
(N
 m
)—
S,
 ha
nd
gr
ip
 
str
en
gt
h (
kg
)—
S 
an
d 
ju
m
p h
eig
ht
 du
rin
g 
th
e o
ne
 le
g h
op
 te
st 
(c
m
)—
S
M
od
er
ate
Oral Contraceptives and Exercise Performance
Ta
bl
e 
2 
 (c
on
tin
ue
d)
St
ud
y
Ai
m
Pa
rti
cip
an
t h
ea
lth
 an
d 
tra
in
in
g s
tat
us
St
ud
y d
es
ig
n
Or
al 
co
nt
ra
ce
pt
ive
 pi
ll 
ty
pe
Eu
m
en
or
rh
eic
 g
ro
up
 
de
sc
rip
tio
n
Ex
er
cis
e o
ut
co
m
es
Qu
ali
ty
 ra
tin
g
El
lio
tt 
et 
al.
 [5
]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 an
d M
C 
on
 m
ax
im
um
 fo
rc
e 
pr
od
uc
tio
n
He
alt
hy
 w
om
en
 (2
2 ±
 4 
ye
ar
s) 
wh
o w
er
e 
se
de
nt
ar
y (
de
fin
ed
 as
 
no
t b
ein
g i
nv
ol
ve
d i
n 
a s
tre
ng
th
 or
 ae
ro
bi
c 
tra
in
in
g p
ro
gr
am
 
fo
r t
he
 pr
ev
io
us
 
6 m
on
th
s)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
Co
m
bi
ne
d m
on
op
ha
sic
 
OC
Ps
 (M
icr
og
yn
on
, 
Br
ev
in
or
, O
va
rn
ett
e, 
M
ar
va
lo
n, 
Ci
les
t)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
(m
ea
n 
cy
cle
 le
ng
th
 of
 
29
 da
ys
) w
ho
 w
er
e 
no
t t
ak
in
g a
ny
 
ho
rm
on
al 
ba
se
d c
on
-
tra
cti
on
 fo
r 6
 m
on
th
s 
pr
io
r t
o t
he
 st
ud
y, 
tes
ted
 du
rin
g t
he
 
EF
 an
d M
L 
ph
as
es
, 
ve
rifi
ed
 by
 B
BT
, 
ur
in
ar
y o
vu
lat
io
n 
de
tec
tio
n t
es
t a
nd
 
se
ru
m
 oe
str
og
en
 an
d 
pr
og
es
ter
on
e
M
ax
im
al 
vo
lu
nt
ar
y 
iso
m
etr
ic 
fo
rc
e o
f t
he
 
fir
st 
do
rsa
l i
nt
er
os
-
se
us
 m
us
cle
 (N
)—
S,
 
iso
ki
ne
tic
 ex
ten
-
sio
n a
nd
 fl
ex
io
n o
f 
th
e q
ua
dr
ice
ps
 an
d 
ha
m
str
in
g m
us
cle
s 
at 
1.0
4. 
2.0
9 a
nd
 
4.1
9 r
ad
/S
 (N
 m
)—
S,
 
an
d i
so
m
etr
ic 
ex
ten
-
sio
n a
nd
 fl
ex
io
n 
(N
 m
)—
S
M
od
er
ate
Gi
ac
om
on
i a
nd
 F
al-
ga
ire
tte
 [4
3]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 ti
m
e o
f d
ay
 
an
d O
CP
 us
e o
n 
m
ax
im
um
 an
ae
ro
bi
c 
po
we
r
Ph
ys
ica
l e
du
ca
tio
n 
stu
de
nt
s (
22
.8 
± 
2.8
 
ye
ar
s)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
Co
m
bi
ne
d m
on
op
ha
sic
 
OC
P 
(0
.02
–0
.03
 m
g 
eth
iny
les
tra
di
ol
 an
d 
0.1
50
 m
g d
es
-
og
es
tre
l o
r 0
.07
5 m
g 
ge
sto
de
ne
)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
las
tin
g 
25
–3
1 d
ay
s i
n l
en
gt
h, 
wh
o h
ad
 no
t u
se
d 
an
y O
CP
 fo
r a
t l
ea
st 
4 m
on
th
s b
efo
re
 
en
ter
in
g t
he
 st
ud
y, 
tes
ted
 du
rin
g t
he
 L
F 
an
d M
L,
 ve
rifi
ed
 by
 
se
ru
m
 oe
str
og
en
 an
d 
pr
og
es
ter
on
e l
ev
els
Pe
ak
 ve
lo
cit
y (
rp
m
)—
E,
 pe
ak
 fo
rc
e (
kg
)—
S 
an
d p
ea
k p
ow
er
 
(W
)—
E,
 m
ea
su
re
d 
du
rin
g a
 fo
rc
e v
elo
c-
ity
 te
st
M
od
er
ate
Gi
ac
om
on
i e
t a
l. 
[2
2]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 an
d e
um
en
or
-
rh
eic
 M
C 
on
 an
ae
ro
-
bi
c p
er
fo
rm
an
ce
Ph
ys
ica
l e
du
ca
tio
n s
tu
-
de
nt
s (
23
 ±
 3 
ye
ar
s)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
Co
m
bi
ne
d m
on
o-
ph
as
ic 
OC
P 
wi
th
 
co
ns
tan
t o
es
tro
ge
n 
an
d p
ro
ge
ste
ro
ne
 
lev
els
 (0
.02
–0
.03
 m
g 
eth
iny
les
tra
di
ol
 an
d 
0.1
50
 m
g d
es
-
og
es
tre
l o
r 0
.07
5 m
g 
ge
sto
de
ne
)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
las
tin
g 
25
–3
1 d
ay
s i
n l
en
gt
h, 
wh
o h
ad
 no
t u
se
d 
an
y O
CP
 fo
r a
t l
ea
st 
4 m
on
th
s b
efo
re
 
en
ter
in
g t
he
 st
ud
y, 
tes
ted
 du
rin
g t
he
 L
F 
an
d M
L,
 ve
rifi
ed
 by
 
se
ru
m
 oe
str
og
en
 an
d 
pr
og
es
ter
on
e l
ev
els
Pe
ak
 ve
lo
cit
y (
rp
m
)—
E,
 pe
ak
 fo
rc
e (
kg
)—
S 
an
d p
ea
k p
ow
er
 
(W
)—
E,
 m
ea
su
re
d 
du
rin
g a
 fo
rc
e v
elo
c-
ity
 te
st 
an
d j
um
p 
he
ig
ht
 (c
m
) m
ea
su
re
d 
us
in
g m
ul
ti 
an
d s
qu
at 
ju
m
p t
es
ts—
S
M
od
er
ate
 K. J. Elliott-Sale et al.
Ta
bl
e 
2 
 (c
on
tin
ue
d)
St
ud
y
Ai
m
Pa
rti
cip
an
t h
ea
lth
 an
d 
tra
in
in
g s
tat
us
St
ud
y d
es
ig
n
Or
al 
co
nt
ra
ce
pt
ive
 pi
ll 
ty
pe
Eu
m
en
or
rh
eic
 g
ro
up
 
de
sc
rip
tio
n
Ex
er
cis
e o
ut
co
m
es
Qu
ali
ty
 ra
tin
g
Go
rd
on
 et
 al
. [
44
]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 an
d M
C 
on
 
pe
ak
 is
ok
in
eti
c t
or
qu
e
He
alt
hy
, w
ell
-tr
ain
ed
 
wo
m
en
 (2
0.6
 ±
 1.
2 
ye
ar
s)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
M
on
op
ha
sic
 O
CP
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
(m
ea
n 
cy
cle
 le
ng
th
 of
 
28
 da
ys
) t
es
ted
 
du
rin
g t
he
 E
F,
 L
F,
 
M
L 
an
d L
L 
ph
as
es
, 
ve
rifi
ed
 by
 sa
liv
ar
y 
oe
str
og
en
 an
d p
ro
-
ge
ste
ro
ne
 le
ve
ls
Pe
ak
 co
nc
en
tri
c k
ne
e 
fle
xo
r a
nd
 ex
ten
so
r 
to
rq
ue
 at
 60
, 1
20
, 1
8-
 
an
d 2
40
° (
N 
m
)—
S
Ve
ry
 lo
w
Go
rd
on
 et
 al
. [
45
]
To
 m
ea
su
re
 th
e 
eff
ec
t o
f O
CP
 an
d 
eu
m
en
or
rh
eic
 M
C 
on
 
in
cid
en
ce
 of
 ̇ V
O 2
 m
ax
 
pl
ate
au
 an
d a
ss
oc
i-
ate
d c
ar
di
or
es
pi
ra
to
ry
 
dy
na
m
ics
He
alt
hy
, p
hy
sic
all
y 
ac
tiv
e w
om
en
 
(2
1 ±
 1.
8 y
ea
rs)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
M
on
op
ha
sic
 O
CP
 co
n-
tai
ni
ng
 30
 µg
 et
hi
ny
l 
oe
str
ad
io
l a
nd
 15
0 µ
g 
lev
on
or
ge
str
el
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
tes
ted
 
du
rin
g t
he
 E
F,
 L
F,
 
M
L 
an
d L
L,
 ve
rifi
ed
 
by
 M
C 
hi
sto
ry
 an
d 
sa
liv
ar
y o
es
tro
ge
n 
an
d p
ro
ge
ste
ro
ne
 
lev
els
Pe
ak
 ̇ V
O 2
 (L
·m
in
−1
) 
an
d p
ow
er
 (W
) 
m
ea
su
re
d d
ur
in
g a
n 
in
cr
em
en
tal
 ru
n t
o 
vo
lit
io
na
l f
ati
gu
e—
E
M
od
er
ate
Gr
uc
za
 et
 al
. [
46
]
To
 m
ea
su
re
 th
e 
eff
ec
t o
f O
CP
 an
d 
eu
m
en
or
rh
eic
 M
C 
on
 
th
er
m
os
en
sit
iv
ity
He
alt
hy
 w
om
en
 
(2
1.3
 ±
 1.
8 y
ea
rs)
 
wh
o w
er
e u
nd
er
tak
-
in
g a
pp
ro
xi
m
ate
ly
 
2–
3 h
 of
 va
rio
us
 
ac
tiv
ity
 ty
pe
s p
er
 
we
ek
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
M
on
op
ha
sic
 O
CP
 
(T
rik
vi
lar
 or
 N
eo
-
Ge
nt
ro
l 1
50
/3
0)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
fo
r 
on
e y
ea
r p
re
ce
d-
in
g t
he
 ex
pe
rim
en
t 
an
d w
ho
 ha
d n
ev
er
 
tak
en
 O
CP
s, 
tes
ted
 
du
rin
g t
he
 L
F 
an
d 
M
L 
ph
as
e, 
ve
rifi
ed
 
by
 B
BT
̇ V
O 2
 pe
ak
 
(m
l·k
g·m
in
−1
)  
m
ea
su
re
d d
ur
in
g a
n 
in
cr
em
en
tal
 cy
cle
 to
 
vo
lit
io
na
l f
ati
gu
e—
E
Lo
w
Gr
uc
za
 et
 al
. [
47
]
To
 m
ea
su
re
 th
e 
eff
ec
t o
f O
CP
 an
d 
eu
m
en
or
rh
eic
 M
C 
on
 ca
rd
io
re
sp
ira
to
ry
 
re
sp
on
se
s t
o e
xe
rc
ise
He
alt
hy
 un
ive
rsi
ty
 
stu
de
nt
s (
21
.3 
± 
1.8
 
ye
ar
s)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
M
on
op
ha
sic
 O
CP
 
(T
rik
vi
lar
 or
 N
eo
-
Ge
nt
ro
l)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
fo
r 
1 y
ea
r p
re
ce
di
ng
 
th
e e
xp
er
im
en
t a
nd
 
wh
o h
ad
 ne
ve
r t
ak
en
 
OC
Ps
, t
es
ted
 du
r-
in
g t
he
 L
F 
an
d M
L 
ph
as
e, 
ve
rifi
ed
 by
 
BB
T
̇ V
O 2
 pe
ak
 
(m
l·k
g·m
in
−1
) 
m
ea
su
re
d d
ur
in
g a
n 
in
cr
em
en
tal
 cy
cle
 to
 
vo
lit
io
na
l f
ati
gu
e—
E
Lo
w
Oral Contraceptives and Exercise Performance
Ta
bl
e 
2 
 (c
on
tin
ue
d)
St
ud
y
Ai
m
Pa
rti
cip
an
t h
ea
lth
 an
d 
tra
in
in
g s
tat
us
St
ud
y d
es
ig
n
Or
al 
co
nt
ra
ce
pt
ive
 pi
ll 
ty
pe
Eu
m
en
or
rh
eic
 g
ro
up
 
de
sc
rip
tio
n
Ex
er
cis
e o
ut
co
m
es
Qu
ali
ty
 ra
tin
g
Hi
ck
s e
t a
l. 
[4
8]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 an
d e
um
en
or
-
rh
eic
 M
C 
on
 ex
er
cis
e 
in
du
ce
d m
us
cle
 
da
m
ag
e, 
an
d t
en
do
n 
pr
op
er
tie
s
He
alt
hy
, r
ec
re
ati
on
-
all
y a
cti
ve
 w
om
en
 
(2
2.3
 ±
 2.
3 y
ea
rs)
Pa
ra
lle
l g
ro
up
, i
nt
er-
ve
nt
io
n, 
re
pe
ate
d 
m
ea
su
re
s
Co
m
bi
ne
d m
on
op
ha
sic
 
OC
P 
wi
th
 et
hi
ny
l 
oe
str
ad
io
l d
os
ag
e 
be
tw
ee
n 2
0 a
nd
 
30
 µg
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
(av
er-
ag
e c
yc
le 
len
gt
h o
f 
28
 da
ys
) a
nd
 w
ho
 
ha
d n
ev
er
 ta
ke
n t
he
 
OC
P, 
tes
ted
 du
rin
g 
th
e o
vu
lat
or
y p
ha
se
, 
ve
rifi
ed
 by
 se
ru
m
 
oe
str
og
en
Pe
ak
 vo
lu
nt
ar
y i
so
m
et-
ric
 to
rq
ue
 (N
 m
)—
S
M
od
er
ate
Isa
cc
o e
t a
l. 
[4
9]
To
 m
ea
su
re
 th
e 
eff
ec
t o
f O
CP
 an
d 
eu
m
en
or
rh
eic
 M
C 
on
 li
pi
d o
xi
da
tio
n 
an
d c
ar
di
or
es
pi
ra
to
ry
 
pa
ra
m
ete
rs 
at 
th
e 
an
ae
ro
bi
c t
hr
es
h-
ol
d a
nd
 m
ax
im
um
 
ca
pa
cit
y
W
eig
ht
 st
ab
le,
 he
alt
hy
 
wo
m
en
 (2
2 ±
 2.
9 
ye
ar
s) 
wh
o w
er
e 
re
cr
ea
tio
na
lly
 ac
tiv
e 
(d
efi
ne
d a
s t
ho
se
 no
t 
inv
ol
ve
d i
n a
ny
 re
gu
-
lar
 ex
er
cis
e t
ra
in
in
g)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
Lo
w-
do
se
 m
on
op
ha
sic
 
OC
P 
co
nt
ain
ed
 20
 ( 
n =
 8)
 or
 30
 ( 
n =
 3)
 
µg
 of
 et
hi
ny
les
tra
di
ol
 
an
d g
es
to
de
ne
 or
 
lev
on
or
ge
str
el
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
(av
er-
ag
e c
yc
le 
len
gt
h o
f 
28
 da
ys
 fo
r a
t l
ea
st 
1 y
ea
r) 
an
d h
ad
 no
t 
tak
en
 an
y O
CP
 fo
r 
m
or
e t
ha
n 1
 ye
ar
 
pr
io
r t
o t
he
 st
ud
y 
be
gi
nn
in
g, 
tes
ted
 
du
rin
g t
he
 M
L 
ph
as
e, 
ve
rifi
ed
 by
 co
un
tin
g 
of
 da
ys
 an
d s
er
um
 
oe
str
og
en
 an
d p
ro
-
ge
ste
ro
ne
 le
ve
ls
̇ V
O 2
 pe
ak
 
(m
l·k
g·m
in
−1
) 
m
ea
su
re
d d
ur
in
g a
n 
in
cr
em
en
tal
 cy
cle
 to
 
vo
lit
io
na
l f
ati
gu
e—
E
M
od
er
ate
Jo
yc
e e
t a
l. 
[1
3]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 lo
ng
-te
rm
 O
CP
 
us
e o
n e
nd
ur
an
ce
 
pe
rfo
rm
an
ce
He
alt
hy
 w
om
en
 
(2
1 ±
 2.
7 y
ea
rs)
 w
ho
 
we
re
 re
cr
ea
tio
na
lly
 
ac
tiv
e (
de
fin
ed
 as
 
ex
er
cis
in
g >
 3 
da
ys
 
pe
r w
ee
k f
or
 at
 le
as
t 
30
 m
in
 pe
r s
es
sio
n)
Pa
ra
lle
l g
ro
up
, 
ob
se
rv
ati
on
al,
 si
ng
le 
m
ea
su
re
Co
m
bi
ne
d m
on
op
ha
sic
 
OC
P
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
las
tin
g 
be
tw
ee
n 2
8 a
nd
 
30
 da
ys
 fo
r a
t l
ea
st 
12
 m
on
th
s b
efo
re
 th
e 
stu
dy
, t
es
ted
 du
rin
g 
th
e E
F 
ph
as
e, 
ve
rifi
ed
 
by
 se
ru
m
 oe
str
og
en
 
an
d p
ro
ge
ste
ro
ne
 
lev
els
Pe
ak
 ̇ V
O 2
 (L
·m
in
−1
) 
an
d p
ow
er
 (W
) 
m
ea
su
re
d d
ur
in
g 
an
 in
cr
em
en
tal
 
cy
cle
 to
 vo
lit
io
na
l 
fat
ig
ue
—
E,
 an
d t
im
e 
to
 ex
ha
us
tio
n (
s) 
on
 a 
su
bm
ax
im
al 
cy
cli
ng
 
tes
t—
E
M
od
er
ate
 K. J. Elliott-Sale et al.
Ta
bl
e 
2 
 (c
on
tin
ue
d)
St
ud
y
Ai
m
Pa
rti
cip
an
t h
ea
lth
 an
d 
tra
in
in
g s
tat
us
St
ud
y d
es
ig
n
Or
al 
co
nt
ra
ce
pt
ive
 pi
ll 
ty
pe
Eu
m
en
or
rh
eic
 g
ro
up
 
de
sc
rip
tio
n
Ex
er
cis
e o
ut
co
m
es
Qu
ali
ty
 ra
tin
g
Jo
yc
e e
t a
l. 
[5
0]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 se
x a
nd
 O
CP
 on
 
su
bm
ax
im
al 
cy
cli
ng
 
pe
rfo
rm
an
ce
 fo
l-
lo
wi
ng
 an
 ec
ce
nt
ric
 
ex
er
cis
e p
ro
to
co
l
He
alt
hy
 w
om
en
 
(2
0.8
 ±
 2.
4 y
ea
rs)
 
wh
o w
er
e r
eg
ul
ar
ly
 
ph
ys
ica
lly
 ac
tiv
e, 
bu
t n
ot
 pa
rti
cip
at-
in
g i
n a
ny
 re
gu
lar
 
re
sis
tan
ce
-e
xe
rc
ise
 
tra
in
in
g
Pa
ra
lle
l g
ro
up
, i
nt
er-
ve
nt
io
n, 
re
pe
ate
d 
m
ea
su
re
s
Co
m
bi
ne
d m
on
op
ha
sic
 
OC
P
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
las
tin
g 
be
tw
ee
n 2
8 a
nd
 
30
 da
ys
 fo
r a
t l
ea
st 
12
 m
on
th
s b
efo
re
 th
e 
stu
dy
, t
es
ted
 du
rin
g 
th
e E
F 
ph
as
e a
nd
 
ve
rifi
ed
 se
ru
m
 oe
s-
tro
ge
n a
nd
 pr
og
es
ter
-
on
e l
ev
els
Pe
ak
 ̇ V
O 2
 
(m
l·k
g·m
in
−1
) a
nd
 
po
we
r (
W
) m
ea
su
re
d 
du
rin
g a
n i
nc
re
m
en
-
tal
 cy
cle
 to
 vo
lit
io
na
l 
fat
ig
ue
—
E,
 an
d m
ea
n 
to
rq
ue
 (N
 m
·kg
−1
) 
an
d t
or
qu
e d
ec
lin
e 
(N
 m
) m
ea
su
re
d 
ac
ro
ss
 24
0 m
ax
im
al 
ec
ce
nt
ric
 qu
ad
ric
ep
s 
co
nt
ra
cti
on
s—
S
Lo
w
Le
br
un
 et
 al
. [
23
]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 an
d e
um
en
or
-
rh
eic
 M
C 
on
 ex
er
cis
e 
pe
rfo
rm
an
ce
 in
 
hi
gh
ly
 ac
tiv
e w
om
en
He
alt
hy
, a
th
let
ic 
wo
m
en
 (1
8–
40
 
ye
ar
s),
 bu
t n
on
e t
ha
t 
co
m
pe
ted
 in
 ae
ro
bi
c 
ac
tiv
iti
es
 (c
yc
lin
g, 
tri
ath
lo
n, 
ro
wi
ng
, 
cr
os
s-c
ou
nt
ry
 sk
iin
g)
Ra
nd
om
ise
d c
on
tro
lle
d 
tri
al
Tr
ip
ha
sic
 O
CP
 (S
yn
-
ph
as
ic,
 0.
03
5 m
g 
eth
iny
les
tra
di
ol
 an
d 
0.5
–1
.0 
m
g n
or
eth
in
-
dr
on
e)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d 
na
tu
ra
l m
on
th
ly
 
M
C 
(2
4–
35
 da
ys
 in
 
len
gt
h)
 an
d n
o O
CP
 
us
e i
n t
he
 3 
m
on
th
s 
be
fo
re
 en
ter
in
g t
he
 
stu
dy
, t
es
ted
 du
rin
g 
th
e E
F 
an
d M
L 
ph
as
es
, v
er
ifi
ed
 by
 
se
ru
m
 oe
str
og
en
 an
d 
pr
og
es
ter
on
e l
ev
els
̇ V
O 2
 pe
ak
 (L
·m
in
−1
) 
m
ea
su
re
d d
ur
in
g a
n 
in
cr
em
en
tal
 cy
cle
 to
 
vo
lit
io
na
l f
ati
gu
e—
E,
 
tim
e t
o e
xh
au
sti
on
 
(s)
 in
 a 
su
bm
ax
im
al 
en
du
ra
nc
e t
es
t—
E,
 
tim
e t
o e
xh
au
sti
on
 
(s)
 in
 an
 an
ae
ro
bi
c 
sp
ee
d t
es
t—
E 
an
d 
pe
ak
 qu
ad
ric
ep
s a
nd
 
ha
m
str
in
g t
or
qu
e 
(N
 m
)—
S
M
od
er
ate
Le
e e
t a
l. 
[5
1]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 an
d e
um
en
or
-
rh
eic
 M
C 
on
 an
ter
io
r 
cr
uc
iat
e l
ig
am
en
t 
ela
sti
cit
y, 
fo
rc
e t
o fl
ex
 
th
e k
ne
e a
nd
 kn
ee
 
fle
xi
on
–e
xt
en
sio
n 
hy
ste
re
sis
He
alt
hy
, n
on
-a
th
let
ic 
wo
m
en
 (2
4.7
 ±
 2 
ye
ar
s)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
Lo
w 
do
se
 O
CP
 
co
nt
ain
in
g <
 50
 µg
 
eth
iny
l-e
str
ad
io
l
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
fo
r a
t 
lea
st 
6 m
on
th
s, 
wi
th
 
an
 av
er
ag
e c
yc
le 
len
gt
h o
f 2
9 d
ay
s, 
tes
ted
 du
rin
g t
he
 E
F,
 
LF
, o
vu
lat
or
y a
nd
 
M
L 
ph
as
es
, v
er
ifi
ed
 
by
 se
ru
m
 oe
str
og
en
 
an
d p
ro
ge
ste
ro
ne
 
lev
els
Kn
ee
 fl
ex
io
n f
or
ce
 
(N
)—
S
M
od
er
ate
Oral Contraceptives and Exercise Performance
Ta
bl
e 
2 
 (c
on
tin
ue
d)
St
ud
y
Ai
m
Pa
rti
cip
an
t h
ea
lth
 an
d 
tra
in
in
g s
tat
us
St
ud
y d
es
ig
n
Or
al 
co
nt
ra
ce
pt
ive
 pi
ll 
ty
pe
Eu
m
en
or
rh
eic
 g
ro
up
 
de
sc
rip
tio
n
Ex
er
cis
e o
ut
co
m
es
Qu
ali
ty
 ra
tin
g
Ly
nc
h a
nd
 N
im
m
o [
52
]
To
 m
ea
su
re
 th
e 
eff
ec
t o
f O
CP
 an
d 
eu
m
en
or
rh
eic
 M
C 
on
 
in
ter
m
itt
en
t e
xe
rc
ise
 
pe
rfo
rm
an
ce
He
alt
hy
 w
om
en
 
(2
5.3
 ±
 6 
ye
ar
s) 
wh
o 
we
re
 re
cr
ea
tio
na
lly
 
ac
tiv
e b
ut
 no
t t
ra
in
in
g 
fo
r a
ny
 on
e s
po
rt 
ex
clu
siv
ely
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
Lo
w-
do
se
 m
on
op
ha
sic
 
OC
P 
(F
em
od
en
e, 
Ci
les
t, 
Ov
ra
ne
tte
, 
M
icr
og
yn
on
)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 ov
ul
ato
ry
 
M
Cs
 w
ith
 an
 av
er-
ag
e c
yc
le 
len
gt
h o
f 
29
 da
ys
, a
nd
 w
ho
 ha
d 
eit
he
r n
ev
er
 ta
ke
n 
OC
Ps
 or
 ha
d n
ot
 
tak
en
 an
 O
CP
 in
 th
e 
las
t 4
 m
on
th
s, 
tes
ted
 
du
rin
g t
he
 L
F 
an
d L
L 
ph
as
es
, v
er
ifi
ed
 by
 
se
ru
m
 pr
og
es
ter
on
e 
lev
els
̇ V
O 2
 pe
ak
 
(m
l·k
g·m
in
−1
) 
m
ea
su
re
d d
ur
in
g a
n 
in
cr
em
en
tal
 ru
n t
o 
vo
lit
io
na
l f
ati
gu
e—
E,
 an
d t
im
e t
o 
ex
ha
us
tio
n (
s) 
in
 an
 
in
ter
m
itt
en
t s
pr
in
t 
tes
t—
E
M
od
er
ate
/ l
ow
Ly
nc
h e
t a
l. 
[5
3]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 on
 pe
rfo
r-
m
an
ce
 an
d m
eta
bo
lic
 
re
sp
on
se
s t
o, 
in
ter
-
m
itt
en
t e
xe
rc
ise
 du
r-
in
g t
he
  1s
t  o
r  3
rd
 w
ee
k 
of
 th
e O
CP
 cy
cle
He
alt
hy
, u
nt
ra
in
ed
 
wo
m
en
 (2
3.1
 ±
 4 
ye
ar
s)
Si
ng
le 
gr
ou
p, 
ob
se
r-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
Lo
w 
do
se
 m
on
op
ha
sic
 
OC
P 
(O
vr
an
ett
e, 
Fe
m
od
en
e, 
M
er-
cil
on
, M
icr
og
yn
on
, 
Br
ev
in
or
)
N/
A
Ti
m
e t
o e
xh
au
sti
on
 (s
) 
in
 th
e fi
na
l s
pr
in
t o
f 
an
 in
ter
m
itt
en
t s
pr
in
t 
pr
ot
oc
ol
—
E
M
od
er
ate
M
ac
ka
y e
t a
l. 
[6
7]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 us
e o
n i
nd
i-
re
ct 
m
ar
ke
rs 
of
 m
us
-
cle
 da
m
ag
e f
ol
lo
wi
ng
 
ec
ce
nt
ric
 cy
cli
ng
 in
 
wo
m
en
He
alt
hy
 w
om
en
 
(2
7.7
 ±
 4.
5 y
ea
rs)
 
wh
o w
er
e n
ot
 ac
tiv
ely
 
pa
rti
cip
ati
ng
 in
 an
y 
re
sis
tan
ce
 or
 fl
ex
-
ib
ili
ty
 tr
ain
in
g i
n t
he
 
6 m
on
th
s p
rio
r t
o t
he
 
stu
dy
Pa
ra
lle
l g
ro
up
, a
cu
te 
in
ter
ve
nt
io
n, 
sin
gl
e 
m
ea
su
re
Th
ird
 an
d f
ou
rth
 
ge
ne
ra
tio
n m
on
o-
ph
as
ic 
OC
P 
(e
th
iny
l 
es
tra
di
ol
 0.
02
 µg
; 
dr
os
pi
re
no
ne
 3 
µg
)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d 
na
tu
ra
l m
on
th
ly
 M
C 
(b
etw
ee
n 2
4 a
nd
 
35
 da
ys
) a
nd
 w
ho
 
we
re
 no
t u
sin
g a
ny
 
fo
rm
 of
 ho
rm
on
e-
ba
se
d c
on
tra
ce
pt
ive
 
m
eth
od
s f
or
 6 
m
on
th
s 
pr
io
r t
o t
he
 st
ud
y, 
tes
ted
 du
rin
g t
he
 ov
u-
lat
or
y p
ha
se
, v
er
ifi
ed
 
by
 ur
in
ar
y o
vu
lat
io
n 
de
tec
tio
n k
it 
an
d s
ali
-
va
ry
 oe
str
og
en
 an
d 
pr
og
es
ter
on
e l
ev
els
̇ V
O 2
 pe
ak
 
(m
l·k
g·m
in
−1
) m
ea
s-
ur
ed
 du
rin
g a
n i
nc
re
-
m
en
tal
 cy
cli
ng
 te
st 
to
 
vo
lit
io
na
l f
ati
gu
e—
E,
 
m
ax
im
al 
vo
lu
n-
tar
y k
ne
e e
xt
en
so
r 
co
nt
ra
cti
on
 at
 90
% 
kn
ee
 fl
ex
io
n (
N)
—
S,
 
an
d m
ea
n p
ow
er
 (W
) 
du
rin
g a
n e
cc
en
tri
c 
cy
cli
ng
 te
st—
E
Hi
gh
/ m
od
er
ate
 K. J. Elliott-Sale et al.
Ta
bl
e 
2 
 (c
on
tin
ue
d)
St
ud
y
Ai
m
Pa
rti
cip
an
t h
ea
lth
 an
d 
tra
in
in
g s
tat
us
St
ud
y d
es
ig
n
Or
al 
co
nt
ra
ce
pt
ive
 pi
ll 
ty
pe
Eu
m
en
or
rh
eic
 g
ro
up
 
de
sc
rip
tio
n
Ex
er
cis
e o
ut
co
m
es
Qu
ali
ty
 ra
tin
g
M
att
u e
t a
l. 
[6
8]
To
 m
ea
su
re
 m
ax
im
al 
an
d s
ub
m
ax
im
al 
ex
er
cis
e o
ut
co
m
es
 
at 
di
ffe
re
nt
 ph
as
es
 
of
 th
e m
en
str
ua
l a
nd
 
OC
P 
cy
cle
He
alt
hy
, t
ra
in
ed
, 
wo
m
en
 (2
5.5
 ±
 5.
2 
ye
ar
s) 
wh
o p
er
fo
rm
ed
 
m
od
er
ate
 to
 vi
go
ro
us
 
ph
ys
ica
l a
cti
vi
ty
 
at 
lea
st 
4 t
im
es
 pe
r 
we
ek
, a
nd
 fo
r a
t l
ea
st 
30
 m
in
 pe
r b
ou
t
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
Se
co
nd
 or
 th
ird
 ge
n-
er
ati
on
 m
on
op
ha
sic
 
OC
P 
co
nt
ain
in
g 
be
tw
ee
n 2
0 a
nd
 35
 µg
 
of
 et
hi
ny
l o
es
tra
di
ol
 
an
d 1
00
–2
00
 µg
 of
 
pr
og
es
tin
)
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
(c
yc
le 
be
tw
ee
n 2
1 a
nd
 
35
 da
ys
 in
 le
ng
th
) 
wh
o w
er
e n
on
 
ho
rm
on
al 
co
nt
ra
ce
p-
tiv
e u
se
rs 
fo
r a
t l
ea
st 
12
 m
on
th
s p
rio
r t
o 
th
e s
tu
dy
, t
es
ted
 du
r-
in
g t
he
 L
F 
an
d M
L 
ph
as
es
, t
es
ted
 us
in
g 
ur
in
ar
y o
vu
lat
io
n 
de
tec
tio
n t
es
t
̇ V
O 2
 pe
ak
 (L
·m
in
−1
 or
 
m
l·k
g·m
in
−1
) d
ur
in
g 
an
 in
cr
em
en
tal
 ra
m
p 
tes
t t
o v
ol
iti
on
al 
fat
ig
ue
—
E,
 an
d t
im
e 
to
 ex
ha
us
tio
n (
s) 
du
rin
g a
 co
ns
tan
t 
lo
ad
 te
st 
at 
85
% 
pe
ak
 
po
we
r—
E
Hi
gh
M
in
ah
an
 et
 al
. [
54
]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 se
x a
nd
 O
CP
 in
 th
e 
re
sp
on
se
 to
 m
us
cle
 
da
m
ag
e a
fte
r i
nt
en
se
 
ec
ce
nt
ric
 ex
er
cis
e
He
alt
hy
 w
om
en
 
(2
1 ±
 2.
7 y
ea
rs)
 w
ho
 
we
re
 ha
bi
tu
all
y a
cti
ve
 
(p
rim
ar
ily
 m
od
er
ate
 
in
ten
sit
y e
nd
ur
an
ce
-
ba
se
d a
cti
vi
tie
s),
 bu
t 
wh
o w
er
e n
ot
 un
de
r-
tak
in
g a
 re
sis
tan
ce
 
tra
in
in
g p
ro
gr
am
Pa
ra
lle
l g
ro
up
, i
nt
er-
ve
nt
io
n, 
re
pe
ate
d 
m
ea
su
re
s
Co
m
bi
ne
d m
on
op
ha
sic
 
OC
P
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
th
at 
oc
cu
rre
d e
ve
ry
 
28
–3
0 d
ay
s, 
tes
ted
 
du
rin
g t
he
 E
F 
ph
as
e, 
ve
rifi
ed
 by
 se
ru
m
 
oe
str
og
en
 le
ve
ls
Pe
ak
 an
d m
ea
n i
so
m
et-
ric
 to
rq
ue
 (N
 m
 an
d 
N 
m
·kg
−1
) a
cr
os
s 2
40
 
ec
ce
nt
ric
 co
nt
ra
c-
tio
ns
—
S
Lo
w
M
in
ah
an
 et
 al
. [
55
]
To
 m
ea
su
re
 th
e 
eff
ec
t o
f O
CP
 an
d 
th
e e
um
en
or
rh
eic
 
M
C 
on
 co
re
 bo
dy
 
tem
pe
ra
tu
re
 an
d s
ki
n 
bl
oo
d fl
ow
 at
 re
st 
an
d d
ur
in
g e
xe
rc
ise
 
(te
m
pe
ra
te 
an
d h
ot
 
en
vi
ro
nm
en
ts)
He
alt
hy
 w
om
en
 
(2
2 ±
 3.
4 y
ea
rs)
 w
ho
 
we
re
 re
cr
ea
tio
na
lly
 
ac
tiv
e (
30
0–
50
0 m
in
 
pe
r w
ee
k o
f m
od
er
ate
 
in
ten
sit
y e
xe
rc
ise
)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
Lo
w 
do
se
 co
m
bi
ne
d 
m
on
op
ha
sic
 O
CP
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
(e
ve
ry
 
25
–3
2 d
ay
s) 
fo
r 
m
or
e t
ha
n 1
2 m
on
th
s 
an
d w
ho
 ha
d n
ev
er
 
tak
en
 an
y f
or
m
 of
 
sy
nt
he
tic
 ho
rm
on
es
, 
tes
ted
 du
rin
g t
he
 E
F 
ph
as
e, 
ve
rifi
ed
 by
 
se
ru
m
 oe
str
og
en
 an
d 
pr
og
es
ter
on
e l
ev
els
Pe
ak
 ̇ V
O 2
 
(m
l·k
g·m
in
−1
) a
nd
 
po
we
r (
W
) m
ea
su
re
d 
du
rin
g a
n i
nc
re
m
en
-
tal
 cy
cle
 to
 vo
lit
io
na
l 
fat
ig
ue
—
E,
 an
d 
m
ea
n p
ow
er
 ou
tp
ut
 
(W
) d
ur
in
g a
 3-
sta
ge
 
su
bm
ax
im
al 
tes
t—
E
M
od
er
ate
Or
teg
a-
Sa
nt
os
 et
 al
. 
[5
6]
To
 m
ea
su
re
 th
e 
eff
ec
t o
f O
CP
 an
d 
eu
m
en
or
rh
eic
 M
C 
on
 
su
bs
tra
te 
ox
id
ati
on
 
du
rin
g s
tea
dy
-st
ate
 
ex
er
cis
e
He
alt
hy
 tr
ain
ed
 w
om
en
 
(3
5.6
 ±
 4.
2 y
ea
rs)
 
wh
o w
er
e t
ra
in
in
g i
n 
eit
he
r e
nd
ur
an
ce
 or
 
str
en
gt
h a
cti
vi
tie
s f
or
 
5–
12
 h 
pe
r w
ee
k
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
St
ab
le 
m
on
op
ha
sic
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d n
atu
ra
l 
m
on
th
ly
 M
C 
tes
ted
 
du
rin
g t
he
 E
F,
 L
F 
an
d M
L 
ph
as
e, 
ve
ri-
fie
d b
y M
C 
hi
sto
ry
 
an
d s
er
um
 oe
str
og
en
 
an
d p
ro
ge
ste
ro
ne
̇ V
O 2
 pe
ak
 
(m
l·k
g·m
in
−1
) 
m
ea
su
re
d d
ur
in
g a
n 
in
cr
em
en
tal
 ru
n t
o 
vo
lit
io
na
l f
ati
gu
e—
E
Lo
w
Oral Contraceptives and Exercise Performance
Ta
bl
e 
2 
 (c
on
tin
ue
d)
St
ud
y
Ai
m
Pa
rti
cip
an
t h
ea
lth
 an
d 
tra
in
in
g s
tat
us
St
ud
y d
es
ig
n
Or
al 
co
nt
ra
ce
pt
ive
 pi
ll 
ty
pe
Eu
m
en
or
rh
eic
 g
ro
up
 
de
sc
rip
tio
n
Ex
er
cis
e o
ut
co
m
es
Qu
ali
ty
 ra
tin
g
Pe
ter
s a
nd
 B
ur
ro
ws
 
[5
7]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 th
e a
nd
ro
ge
ni
cit
y 
of
 pr
og
es
tin
s i
n O
CP
 
on
 le
g s
tre
ng
th
Un
ive
rsi
ty
 at
hl
ete
s 
(2
0.2
 ±
 0.
5 y
ea
rs)
 
fro
m
 a 
va
rie
ty
 of
 
sp
or
ts 
(c
ric
ke
t, 
fo
ot
ba
ll,
 en
du
ra
nc
e 
ru
nn
in
g a
nd
 sw
im
-
m
in
g)
Pa
ra
lle
l g
ro
up
, o
bs
er-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
M
on
op
ha
sic
 O
CP
 
co
nt
ain
in
g 3
0 µ
g 
eth
iny
les
tra
di
ol
 w
ith
 
12
0 µ
g l
ev
on
or
g-
es
ter
el 
or
 25
0 µ
g 
no
rg
es
tim
ate
N/
A
Pe
ak
 le
g e
xt
en
sio
n 
an
d fl
ex
io
n t
or
qu
e 
(N
 m
)—
S
M
od
er
ate
Qu
in
n e
t a
l. 
[5
8]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 lo
ng
-te
rm
 O
CP
 
us
e o
n c
er
eb
ra
l 
ox
yg
en
ati
on
 du
rin
g 
in
cr
em
en
tal
 cy
cli
ng
 
to
 ex
ha
us
tio
n
He
alt
hy
 w
om
en
 (2
1 ±
 3 
ye
ar
s) 
wh
o w
er
e 
re
cr
ea
tio
na
lly
-a
cti
ve
 
(d
efi
ne
d a
s 1
50
–
30
0 m
in
 pe
r w
ee
k o
f 
m
od
er
ate
 in
ten
sit
y 
ex
er
cis
e)
Pa
ra
lle
l g
ro
up
, 
ob
se
rv
ati
on
al,
 si
ng
le 
m
ea
su
re
28
-d
ay
 co
m
bi
ne
d 
m
on
op
ha
sic
 O
CP
W
om
en
 w
ith
 a 
se
lf-
re
po
rte
d 
na
tu
ra
l m
on
th
ly
 
M
C 
(2
8–
30
 da
ys
 in
 
len
gt
h)
 an
d h
ad
 no
t 
tak
en
 an
y f
or
m
 of
 
ho
rm
on
al 
co
nt
ra
ce
p-
tio
n f
or
 12
 m
on
th
s 
pr
io
r t
o t
he
 st
ud
y, 
tes
ted
 du
rin
g t
he
 E
F 
ph
as
e, 
ve
rifi
ed
 by
 
se
ru
m
 oe
str
og
en
 an
d 
pr
og
es
ter
on
e l
ev
els
Pe
ak
 ̇ V
O 2
 
(m
l·k
g·m
in
−1
) a
nd
 
po
we
r (
W
) d
ur
in
g a
n 
in
cr
em
en
tal
 cy
cle
 to
 
vo
lit
io
na
l f
ati
gu
e—
E
M
od
er
ate
Re
be
lo
 et
 al
. [
59
]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 on
 pe
ak
 
ae
ro
bi
c c
ap
ac
ity
 
an
d a
t t
he
 an
ae
ro
bi
c 
th
re
sh
ol
d l
ev
el 
in
 
ac
tiv
e a
nd
 se
de
nt
ar
y 
yo
un
g w
om
en
He
alt
hy
 w
om
en
 
(2
3 ±
 2.
1 y
ea
rs)
, w
ho
 
we
re
 ac
tiv
e (
ru
nn
in
g 
or
 sp
in
ni
ng
 4–
5 t
im
es
 
pe
r w
ee
k)
 or
 se
de
n-
tar
y (
no
t e
ng
ag
in
g 
in
 re
gu
lar
 ph
ys
ica
l 
ac
tiv
ity
 fo
r t
he
 pr
ev
i-
ou
s 1
2 m
on
th
s)
Pa
ra
lle
l g
ro
up
, 
ob
se
rv
ati
on
al,
 si
ng
le 
m
ea
su
re
M
on
op
ha
sic
 O
CP
 
(0
.2 
m
g e
th
iny
le-
str
ad
io
l a
nd
 0.
15
 m
g 
ge
sto
de
ne
)
N/
A
Pe
ak
 ̇ V
O 2
 
(m
l·k
g·m
in
−1
) a
nd
 
po
we
r (
W
) d
ur
in
g a
n 
in
cr
em
en
tal
 cy
cle
 to
 
vo
lit
io
na
l f
ati
gu
e—
E
M
od
er
ate
Re
ch
ich
i e
t a
l. 
[6
0]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 cy
cle
 on
 
en
du
ra
nc
e p
er
fo
r-
m
an
ce
Tr
ain
ed
 cy
cli
sts
 an
d 
tri
ath
let
es
 (3
4 ±
 7 
ye
ar
s)
Si
ng
le 
gr
ou
p, 
re
pe
ate
d 
m
ea
su
re
s, 
ob
se
rv
a-
tio
na
l
M
on
op
ha
sic
 O
CP
 (2
0–
35
 µg
 et
hi
ny
les
tra
di
ol
 
an
d 1
00
–3
00
0 µ
g 
pr
og
es
tin
)
N/
A
M
ea
n p
ow
er
 ou
tp
ut
 
(W
) d
ur
in
g a
 1 
h 
tim
e-
tri
al—
E
Hi
gh
 K. J. Elliott-Sale et al.
Ta
bl
e 
2 
 (c
on
tin
ue
d)
St
ud
y
Ai
m
Pa
rti
cip
an
t h
ea
lth
 an
d 
tra
in
in
g s
tat
us
St
ud
y d
es
ig
n
Or
al 
co
nt
ra
ce
pt
ive
 pi
ll 
ty
pe
Eu
m
en
or
rh
eic
 g
ro
up
 
de
sc
rip
tio
n
Ex
er
cis
e o
ut
co
m
es
Qu
ali
ty
 ra
tin
g
Re
ch
ich
i e
t a
l. 
[1
9]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 cy
cle
 on
 
co
m
m
on
 te
am
 sp
or
t 
pe
rfo
rm
an
ce
 va
ri-
ab
les
Te
am
 sp
or
t a
th
let
es
 
(2
3.5
 ±
 4.
5 y
ea
rs)
Si
ng
le 
gr
ou
p, 
ob
se
r-
va
tio
na
l, 
re
pe
ate
d 
m
ea
su
re
s
M
on
op
ha
sic
 O
CP
 
(3
0 m
cg
 et
hi
ny
le-
str
ad
io
l w
ith
 15
0 
m
cg
 le
vo
no
rg
es
tre
l, 
20
00
 m
cg
 cy
pr
ot
er-
on
e a
ce
tat
e, 
3 m
g 
dr
os
pi
re
no
ne
 or
 50
0 
m
cg
 no
re
th
ist
er
on
e)
N/
A
Ju
m
p h
eig
ht
 (c
m
) 
m
ea
su
re
d d
ur
in
g 
a c
ou
nt
er
m
ov
e-
m
en
t a
nd
 a 
re
ac
tiv
e 
str
en
gt
h (
30
 an
d 
45
 cm
) j
um
ps
—
S;
 
10
 s 
cy
cle
 pe
ak
 
po
we
r (
W
·kg
−1
) 
an
d t
ot
al 
wo
rk
 do
ne
 
(J·
kg
−1
)—
E;
 5X
6 
se
co
nd
 re
pe
ate
d 
sp
rin
t t
ot
al 
wo
rk
 
(J·
kg
−1
) a
nd
 po
we
r 
de
cr
em
en
t (
%)
—
E
Hi
gh
Re
ch
ich
i e
t a
l. 
[2
4]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 cy
cle
 on
 
20
0 m
 sw
im
m
in
g 
pe
rfo
rm
an
ce
 an
d 
as
so
cia
ted
 m
ea
su
re
s 
of
 he
ar
t r
ate
, b
lo
od
 
lac
tat
e, 
pH
 an
d b
lo
od
 
gl
uc
os
e
Co
m
pe
tit
ive
 sw
im
m
er
s 
an
d w
ate
r p
ol
o p
lay
-
er
s (
26
 ±
 4 
ye
ar
s)
Si
ng
le 
gr
ou
p, 
re
pe
ate
d 
m
ea
su
re
s, 
ob
se
rv
a-
tio
na
l
M
on
op
ha
sic
 O
CP
 
(3
0 µ
g e
th
iny
le-
str
ad
io
l a
nd
 15
0 µ
g 
lev
on
or
ge
str
el)
N/
A
Ti
m
e t
o c
om
pl
ete
 (s
) a
 
20
0 m
 sw
im
—
E
Hi
gh
Re
dm
an
 an
d W
ea
th
-
er
by
 [6
1]
To
 m
ea
su
re
 th
e e
ffe
ct 
of
 O
CP
 cy
cle
 on
 
an
ae
ro
bi
c p
er
fo
r-
m
an
ce
El
ite
 an
d s
ub
-e
lit
e r
ow
-
er
s (
20
 ±
 1.
9 y
ea
rs)
Si
ng
le 
gr
ou
p, 
re
pe
ate
d 
m
ea
su
re
s, 
ob
se
rv
a-
tio
na
l
Co
m
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0.31]). Posterior estimates of the pooled effect size identi-
fied a small probability of a small effect favouring naturally 
menstruating women (d ≥ 0.2; p = 0.188) and effectually a 
zero probability favouring habitual OCP women (d ≤  − 0.2; 
p < 0.001). Inclusion of outliers within the model increased 
the average effect size  (ES0.5 = 0.19 [95% CrI  − 0.14 to 
0.51]) and between study variance ( 휏0.5 = 0.71 [95% CrI 
0.49–1.07]).
3.2.3  Sensitivity Analyses; Primary Outcome Studies/
Moderate or High‑Quality Studies only
Sensitivity analyses were completed for between and within 
group designs using data from studies that included exer-
cise performance as the primary study outcome (Table 3) 
and from studies categorised as high or moderate in quality 
(Table 4). No substantive differences were obtained from 
any of the previous analyses with pooled effect sizes iden-
tifying trivial effects with greater performances obtained in 
naturally menstruating women. 
3.2.4  Sensitivity Analysis of Physiological Menstrual Cycle 
Phases Versus Pseudo Oral Contraceptive Pill Phases; 
Days 1–5, Days 12–16 and Days 19–23
An additional set of sensitivity analyses were completed on 
the between group design data to better match the physi-
ological menstrual cycle and OCP pseudo-phases. This 
was achieved by mapping days 1–5, 12–16 and 19–23 from 
both cycles (Table 5). Collectively, findings were aligned 
with the more coarsely matched phases presented above 
(i.e., Sects. 3.2.1 and 3.2.2). In days 1–5 and 19–23, pooled 
effect sizes again identified trivial effects with greater per-
formances obtained in naturally menstruating women. In 
days 12–16, pooled effect sizes were effectually zero with a 
wide CrI reflecting the limited data available (11 effect sizes 
from 5 studies).
3.3  Within Group Analyses of Oral Contraceptive 
Consumption with the Hormone‑Free 
Withdrawal phase
Twenty-four of the included studies (combined quality rat-
ing = H/M; specifically 33% H; 33% M; 17% L; 17% VL) 
generated 148 effect sizes (positive values favouring OCP 
consumption) from research designs comparing OCP con-
sumption with OCP withdrawal. The data were collected 
from 221 participants with studies comprising a mean group 
size of 10 (n = 5–17). The three-level hierarchical model 
incorporating both strength (96 effect sizes) and endurance 
(52 effect sizes) provided some evidence of a trivial effect 
with the pooled effect size very close to zero  (ES0.5 = 0.05 
[95% CrI  − 0.02 to 0.11]; Fig. 5). Between study variance Ta
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was relatively small 휏0.5 = 0.06 [95% CrI 0.0–0.16] as were 
central estimates of intraclass correlation  ICC0.5 = 0.20 [95% 
CrI 0.0–0.62] due to analysis of multiple outcomes reported 
within studies. Pooling of strength and endurance outcomes 
was conducted as no evidence was obtained that indicated 
a differential effect between the performance categories 
 (ES0.5/Endurance-Strength = 0.02 [95% CrI  − 0.22 to 0.33]). Pos-
terior estimates of the pooled effect size identified almost 
zero probability of a small effect in either direction (|d|≥ 0.2 
p ≤ 0.001). Sensitivity analyses conducted with data from 
studies where performance was identified as a primary out-
come had minimal effect on model outputs (Table 3) and 
from studies categorised as high or moderate in quality 
(Table 4) had no substantive influence on model outputs.
3.4  Within Group Comparison of Oral Contraceptive 
Use and Non‑Use
Only two studies [20, 42] met the inclusion criteria for this 
category and as such no meta-analysis was performed on 
these data. Casazza et al. [20] tested participants during two 
phases (4–8 days and 17–25 after the start of menses) of 
the menstrual cycle, in a randomised order. Following this, 
participants began taking the same triphasic OCP for four 
complete cycles (28 days per cycle) and were tested during 
the week of the inactive OCPs and during the second week 
of active OCP ingestion. Menstrual cycle phase had no effect 
on peak exercise capacity. Conversely, 4 months of OCP 
use resulted in significant decreases in time to peak exercise 
Fig. 1  Search flow diagram
 K. J. Elliott-Sale et al.
(14%) and the peak power output attained (8%) during a 
continuously graded cycle test. In addition, all participants 
experienced an 11% decline in peak oxygen uptake ( ̇VO2 peak; 
L∙min−1). Ekenros et al. [42] employed a cross-over design, 
such that participants taking an OCP upon recruitment were 
tested on day 2, 3 or 4 during the OCP free days and on days 
7 or 8 and 14 or 15 during the OCP-taking days, after which 
they stopped taking the OCP and were tested on day 2, 3 
or 4, 48 h after ovulation and 7 or 8 days after ovulation. 
Those who were naturally menstruating at recruitment were 
tested on day 2, 3 or 4, 48 h after ovulation and 7 or 8 days 
after ovulation and were re-tested following one OCP cycle 
on day 2, 3 or 4 during the OCP free days and on days 7 or 
8 and 14 or 15 during the OCP-taking days. There were no 
significant differences in muscle strength between groups, 
although maximum muscle strength of the knee extensors 
was different between the early follicular (days 2, 3 or 4) 
and luteal phase (7 or 8 days after ovulation) in the naturally 
menstruating group; 139 (28) N·m compared with 145 (26) 
N·m (p = 0.02).
Fig. 2  Quality rating of outcomes from all included studies (n = 42). 
Each bar represents the proportion of articles assigned a high, mod-
erate, low, or very low-quality rating. The x-axis represents the dif-
ferent stages of this process, with the first bar based on the assess-
ment of risk of bias and study quality as determined by the Downs 
and Black checklist, while question 1 (Q.1) and question 2 (Q.2) were 
used to determine if the natural menstrual cycle phase comparison 
was verified using appropriate biochemical outcomes and whether 
the oral contraceptive pill under investigation was described in a suffi-
cient level of detail. The final bar represents the proportion of studies 
assigned to each quality rating category
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Fig. 3  Bayesian Forest plot of multilevel meta-analysis compar-
ing performance measured during oral contraceptive pill withdrawal 
phase and early follicular phase of the menstrual cycle. The study-
specific intervals represent individual effect size estimates and sam-
pling error. The circle represents the pooled estimate generated with 
Bayesian inference along with the 95% credible interval (95% CrI)
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3.5  Randomised Controlled Trials of Oral 
Contraceptive Use Versus Placebo Intake
Only one study [23] met the inclusion criteria for this cat-
egory and as such no meta-analysis was performed on these 
data. Lebrun et al. [23] employed a randomised, double-
blind, placebo-controlled trial in naturally menstruating 
women. Testing was performed during the early follicular 
(days 3–8) and mid-luteal (days 4–9 after ovulation) phases 
of an ovulatory menstrual cycle, after which participants 
were randomly assigned to either an OCP (n = 7) or placebo 
(n = 7) group and were tested between days 14 and 17 of the 
second cycle of OCP (i.e., the same triphasic OCP) or pla-
cebo administration. Participants were active women, who 
regularly competed in aerobic activities such as running, 
cycling, triathlon, rowing, cross country skiing. OCP use 
resulted in a mean decrease of 4.7% in ̇VO2max compared 
with a 1.5% improvement in the placebo group. The decrease 
in absolute ̇VO2max was accompanied by an increase in the 
sum of skinfolds, but not by significant changes in weight or 
measures of strength, anaerobic, or endurance performance.
4  Discussion
The aim of this review was to identify if OCP use influ-
enced exercise performance. Results generally indicated a 
trivial performance effect on average with OCP use, with 
superior performance generally observed for naturally men-
struating women compared to their OCP using counterparts. 
In addition to the estimated trivial to small average effect, 
results from the meta-analysis models indicated relatively 
large between study variance indicating that research design, 
participant characteristics and performance measured might 
influence any effect. Collectively, these findings indicate that 
OCPs might, on average, exert a slightly negative impact on 
performance, but from a practical point of view the effect 
magnitude and variability support consideration of an indi-
vidual’s response to OCP use, so that decisions as to the 
appropriateness of OCP use can be tailored to the individ-
ual requirements (e.g., contraceptive or medical need) and 
response (i.e., to what degree they might be affected) of each 
athlete. Pooling of data comparing exercise performance 
between OCP consumption and withdrawal estimated an 
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Fig. 4  Bayesian Forest plot of multilevel meta-analysis comparing 
performance measured during oral contraceptive pill consumption 
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The study-specific intervals represent individual effect size estimates 
and sampling error. The circle represents the pooled estimate gener-
ated with Bayesian inference along with the 95% credible interval 
(95% CrI)
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effect that was very close to zero, indicating that exogenous 
supplementation of oestrogen and progestin is unlikely to 
have any substantive effect on exercise performance across 
an OCP cycle.
As a result of OCP use, endogenous concentrations of 
oestradiol and progesterone are significantly downregulated 
when compared with the mid-luteal phase of the menstrual 
cycle [5]. This chronic downregulation might be responsible 
for the slightly impaired exercise performance demonstrated 
in OCP users when compared with their naturally menstru-
ating counterparts. Indeed, the endogenous hormonal pro-
file of an OCP user is comparable to the profile observed 
during the early follicular phase of the physiological men-
strual cycle; i.e., correspondingly low levels of endogenous 
oestradiol and progesterone [5, 69, 70]. In our meta-analysis 
[71], on the effects of the menstrual cycle on exercise perfor-
mance, the available evidence indicated potentially inferior 
performance during the early follicular phase, when com-
pared with all other phases of the menstrual cycle that had 
considerably higher concentrations of endogenous oestrogen 
and/or progesterone. Similarly, the within group results of 
the current meta-analysis showed that exercise performance 
between the OCP consumption and withdrawal phases was, 
on average, very unlikely to exhibit even a small effect, dur-
ing which time the concentrations of endogenous oestradiol 
and progesterone were consistently low and did not signifi-
cantly increase [5]. Collectively, these results indicate that 
exercise performance might be mediated by the concentra-
tion of endogenous ovarian hormones in some individuals, 
as reflected by evidence of slightly impaired performance on 
average at a time when these hormones are lowest.
The between-group findings from the present review 
align with those of Casazza et al. [20] and Lebrun et al. 
[23] who also showed that experimental OCP use resulted 
in reduced peak exercise capacity and decreased maximal 
oxygen uptake, when compared with non-hormonal con-
traceptive use. Casazza et al. [20] employed a cross-over 
design for their study, with data from two phases of a physi-
ological menstrual cycle compared with data after 4 months 
of triphasic OCP use, whilst Lebrun et al. [23] utilised a 
randomised, double-blind, placebo-controlled trial, with 
data from two phases of the physiological menstrual cycle 
compared with data after 2 months of triphasic OCP use. 
These longitudinal intervention studies represent a change 
from inactive to active OCP use in the same individuals, 
which is a stronger research design when compared to the 
cross-sectional observational studies that were used in the 
between-group analysis in the present review, which fur-
ther supports the notion that OCP use might result in small 
adverse effects on performance in some individuals when 
compared with naturally menstruating women. It is worth 
noting that experimental OCP use may not always be car-
ried out in consultation with a clinician who would monitor Ta
bl
e 
3 
 R
es
ul
ts 
fro
m
 se
ns
iti
vi
ty
 an
aly
se
s w
ith
 da
ta 
fro
m
 st
ud
ies
 in
clu
di
ng
 pe
rfo
rm
an
ce
 as
 th
e p
rim
ar
y o
ut
co
m
e
Re
su
lts
 ar
e f
ro
m
 m
ul
til
ev
el 
ra
nd
om
 eff
ec
ts 
m
od
els
 w
ith
 m
ed
ian
 pa
ra
m
ete
r e
sti
m
ate
s a
nd
 95
% 
cr
ed
ib
le 
in
ter
va
ls 
(9
5%
 C
rI)
H
 hi
gh
, M
 m
od
er
ate
, L
 lo
w,
 V
L 
ve
ry
 lo
w
Se
ns
iti
vi
ty
 an
aly
sis
An
aly
sis
 de
tai
ls
Eff
ec
t s
ize
Be
tw
ee
n s
tu
dy
 va
ria
nc
e
In
tra
cla
ss
 co
rre
lat
io
n
Pr
ob
ab
ili
ty
 of
 sm
all
 eff
ec
t
Be
tw
ee
n g
ro
up
: o
ra
l c
on
tra
ce
pt
ive
 pi
ll 
wi
th
dr
aw
al 
ve
rsu
s t
he
 ea
rly
 fo
lli
cu
lar
 
ph
as
e o
f t
he
 m
en
str
ua
l c
yc
le
34
 eff
ec
t s
ize
s f
ro
m
 11
 st
ud
ies
 (c
om
-
bi
ne
d q
ua
lit
y =
 H
/M
/L
; 2
7%
 H
; 2
7%
 
M
; 2
7%
 L
; 1
8%
 V
L)
0.1
4 [
− 
0.1
4–
0.3
8]
0.2
0 [
0.0
1–
0.5
9]
0.2
8 [
0.0
–0
.82
]
(d
 ≥
 0.
2;
  p
 =
 0.
32
3;
  d
 ≤
  −
 0.
2;
  
p =
 0.
01
4)
Be
tw
ee
n g
ro
up
: o
ra
l c
on
tra
ce
pt
ive
 pi
ll 
co
ns
um
pt
io
n v
er
su
s a
ll 
ph
as
es
 of
 th
e 
m
en
str
ua
l c
yc
le 
ex
ce
pt
 th
e e
ar
ly
 fo
l-
lic
ul
ar
 ph
as
e
57
 eff
ec
t s
ize
s f
ro
m
 16
 st
ud
ies
 (c
om
-
bi
ne
d q
ua
lit
y =
 M
; 2
6.7
% 
H;
 33
.3%
 
M
; 2
6.7
% 
L;
 13
.3%
 V
L)
0.1
4 [
− 
0.0
3–
0.3
1]
0.1
0 [
0.0
–0
.40
]
0.4
2 [
0.0
–0
.86
]
(d
 ≥
 0.
2;
  p
 =
 0.
25
7;
  d
 ≤
  −
 0.
2;
  
p =
 0.
00
1)
W
ith
in
 g
ro
up
: o
ra
l c
on
tra
ce
pt
ive
 pi
ll 
co
ns
um
pt
io
n w
ith
 or
al 
co
nt
ra
ce
pt
ive
 
pi
ll 
wi
th
dr
aw
al
14
1 e
ffe
ct 
siz
es
 fr
om
 21
 st
ud
ies
 (c
om
-
bi
ne
d q
ua
lit
y =
 H
/M
; 3
3.3
% 
H;
 33
.3%
 
M
; 1
9.1
% 
L;
 14
.3%
 V
L)
0.0
5 [
− 
0.0
3–
0.1
1]
0.0
6 [
0.0
–0
.17
]
0.1
9 [
0.0
–0
.66
]
(|d
|≥
 0.
2;
  p
 <
 0.
00
1)
Oral Contraceptives and Exercise Performance
any potentially unfavourable side effects, and possibly make 
changes to the OCP type or dose, as such higher detrimental 
effects may potentially be observed in experimental OCP 
users as opposed to habitual OCP users. In addition, some 
adverse side-effects, which are experienced during initial 
OCP use, can mitigate over time, potentially compounding 
the issue of comparing habitual OCP users with experimen-
tal OCP users.
Ekenros et al. [42] showed no difference in performance 
between OCP and non-OCP use, which is contrary to the 
findings from the present study and those of Casazza et al. 
[20] and Lebrun et al. [23]. Although Ekenros et al. [42] 
employed a longitudinal intervention study design, the 
original ‘non-OCP’ users only received a monophasic OCP 
for 1 month (i.e., 21 OCP-taking days) before they were 
retested as ‘habitual’ OCP users. Casazza et al. [20] and 
Lebrun et al. [23] retested after 4 and 2 months of OCP 
use, which might have resulted in a greater downregula-
tion of endogenous oestradiol and progesterone than that 
seen by Ekenros et al. [42]. In addition, the participants 
in the Ekenros et al. [42] study used a variety of OCPs, 
whereas Casazza et al. [20] and Lebrun et al. [23] used the 
same OCP, resulting in a more homogenous group, with 
potentially less inter-individual variation in endogenous 
Table 4  Results from sensitivity analyses with data from studies categorised as “high” or “moderate” in quality
Results are from multilevel random effects models with median parameter estimates and 95% credible intervals (95% CrI)
H high, M moderate, L low, VL very low
Sensitivity analysis Analysis details Effect size Between study variance Intraclass correlation Probability of small 
effect
Between group: oral 
contraceptive pill 
withdrawal versus the 
early follicular phase 
of the menstrual cycle
22 effect sizes from 9 
studies
0.12 [− 0.24–0.43] 0.18 [0.01–0.61] 0.63 [0.0–0.88] (d ≥ 0.2;  p = 0.281;  
d ≤  − 0.2;  
p = 0.041)
Between group: oral 
contraceptive pill 
consumption versus 
all phases of the men-
strual cycle except the 
early follicular phase
60 effect sizes from 15 
studies
0.14 [− 0.09 to 0.33] 0.22 [0.05–0.48] 0.10 [0.0–0.55] (d ≥ 0.2;  p = 0.282;  
d ≤  − 0.2;  
p = 0.006)
Within group: oral 
contraceptive pill 
consumption with 
oral contraceptive pill 
withdrawal
89 effect sizes from 16 
studies
0.03 [− 0.06 to 0.10] 0.04 [0.0–0.16] 0.38 [0.0–0.69] (|d|≥ 0.2;  p < 0.001)
Table 5  Results from sensitivity analyses comparing performance outcomes comparing physiological menstrual cycle phases versus pseudo oral 
contraceptive pill phases
Results are from multilevel random effects models with median parameter estimates and 95% credible intervals (95% CrI)
H high, M moderate, L low, VL very low
Sensitivity analysis Analysis details Effect size Between study vari-
ance
Intraclass correlation Probability of small 
effect
Between group: days 
1–5
42 effect sizes from 16 
studies (combined 
quality rating = M; 
18.75% H; 31.25% 
M; 25% L; 25% VL)
0.17 [− 0.04 to 0.38] 0.15 [0.01–0.50] 0.60 [0.10–0.90] (d ≥ 0.2;  p = 0.368;  
d ≤  − 0.2;  
p = 0.001)
Between group: days 
12–16
11 effect sizes from 5 
studies (combined 
quality rating = M; 
60% M; 40% VL)
 − 0.04 [− 0.73 to 
0.58]
0.27 [0.01–1.28] 0.20 [0.10–0.70] (d ≥ 0.2;  p = 0.137;  
d ≤  − 0.2;  
p = 0.291)
Between group: days 
19–23
38 effect sizes from 14 
studies (combined 
quality rating = M; 
28.6% H; 35.7% M; 
21.4% L; 14.3% VL)
0.13 [− 0.13 to 0.34] 0.22 [0.02–0.56] 0.35 [0.01–0.65] (d ≥ 0.2;  p = 0.253;  
d ≤  − 0.2;  
p = 0.009)
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ovarian hormone concentration, and reducing the possi-
bility of type II errors [72]. Ekenros et al. [42] used a 
strength based performance measure, whilst Casazza 
et al. [20] and Lebrun et al. [23] employed more endur-
ance type performance measures, representing different 
physiological pathways for oestrogen and/or progesterone 
to exert their effects. For example, progesterone is likely 
to mediate changes in ventilatory drive [73], whilst oestro-
gen might be responsible for sex-differences in substrate 
metabolism [74], both considered to influence endurance 
performance. Whereas for strength-based performance, 
both sex hormones act as neurosteroids, which are capable 
of traversing the blood–brain barrier thereby potentially 
enacting effects on maximal neuromuscular performance 
[75]. These methodological differences, alongside the dif-
fering modes of exercise, might account for the disparity in 
result between Ekenros et al. [42] and Casazza et al. [20], 
Lebrun et al. [23] and the present review.
Our within group analysis indicates that the exogenous 
supplementation of ethinyl oestradiol and progestin is very 
unlikely to exert any substantive effect, such that perfor-
mance was relatively consistent across an OCP cycle. From 
a practical perspective, this means that exercise performance 
is not moderated by the exogenous hormonal profile of an 
OCP but is more likely mediated by the endogenous hormo-
nal milieu caused by OCP use (i.e., the continuous down-
regulation of oestradiol and progesterone between OCP 
consumption and withdrawal). These data suggest that the 
‘supplementary’ nature of OCPs should not be considered 
as performance-enhancing. As OCPs are also not ergolytic, 
the timing of the withdrawal bleed can be manipulated (e.g., 
to avoid bleeding during competition) without negatively 
impacting performance, although the long-term health 
implications of continuous OCP consumption without any 
withdrawal are unknown. Schaumberg et al. [10] have noted 
that menstrual manipulation for exercise and sports perfor-
mance reasons is already a fairly common practice amongst 
physically active women.
Although all results from the current meta-analysis align, 
and have solid mechanistic underpinnings, it is important to 
acknowledge that the practical implications of these find-
ings are small. All point estimates and outliers were in the 
same direction and indicated a potentially negative influ-
ence, on average, of ovarian hormonal suppression on per-
formance. However, the real-life implications of these find-
ings are likely to be so small as to be trivial and therefore not 
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Fig. 5  Bayesian Forest plot of multilevel meta-analysis comparing 
performance measured during oral contraceptive pill consumption 
with the hormone-free withdrawal phase. The study-specific intervals 
represent individual effect size estimates and sampling error. The cir-
cle represents the pooled estimate generated with Bayesian inference 
along with the 95% credible interval (95% CrI)
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meaningful for most of the population. Additionally, a large 
range of moderating factors [76, 77] (independent of hormo-
nal changes) are likely to influence an individual’s response 
to, and requirement for, OCPs and we suggest that indi-
viduals do not solely make their decision to use or not use 
OCPs based on the performance related findings reported 
herein. For example, some individuals are prone to substan-
tial menstrual symptoms such as cramps, bloating or heavy 
menstrual bleeding, and for these individuals, the benefits 
of OCP use [78, 79] might outweigh the small detriments 
observed in the present review. Similarly, the consequences 
of unplanned pregnancy might be far greater than the trivial 
effects observed in the current meta-analysis. Conversely, 
large inter-individual variation exists in the response to 
most interventions [80, 81] whereby some individuals might 
experience no performance-related side-effects whatsoever, 
whereas others might experience substantial performance-
related side-effects from OCP use [4]. As such, we recom-
mend that individuals consider all relevant factors (which 
might include physical, emotional, practical, financial and 
health related aspects) before making decisions as to the 
appropriateness (or not) of OCP use.
The current review was primarily conducted on non-ran-
domised observational trials, which might be considered a 
limitation of its value. Randomised controlled trials are the 
preferred design to investigate the potential influence of a treat-
ment (in this case OCPs) on an outcome (in this case exercise 
performance); however, they can be difficult to implement in 
this population, as individuals tend to be habitual OCP users or 
non-users. Only one randomised controlled trial was identified 
from the relevant literature [23], alongside two further trials 
wherein an OCP was prescribed to or withheld from non-users 
and habitual users in a cross-over design [20, 39]. Withhold-
ing OCPs from a habitual OCP user might have ethical and 
practical (e.g., unplanned pregnancy) implications and as such, 
this type of research design is rarely employed. In addition, 
having the resources to conduct appropriately standardised 
and controlled studies across the time-periods required to 
adequately address this question is, in many cases, prohibitive 
(i.e., an adequate wash-out and/or supplementation period). 
Instead, most data on OCP use versus non-use are based on 
between group investigations of independent parties, which 
might be impacted by a large range of confounding variables 
and does not permit causal inference to be made. The lack of 
randomised controlled trials will affect analyses within this 
area of study for the foreseeable future.
Following the Downs and Black quality assessment [27], 
most studies (64%) were classified as M or L, which was 
largely due to a lack of standardisation (e.g., prior activity 
and food intake) and inadequate familiarisation (i.e., often 
no familiarisation took place or long periods of time had 
elapsed between testing sessions, potentially warranting 
re-familiarisation). Additionally, most studies had small 
samples (range: n = 5–25), with a mean group size of 10, 
meaning that many were likely to be under-powered. Rigor-
ous control of these research design factors in future stud-
ies, along with consideration of individual response [65, 66] 
and more randomised controlled trials will provide further 
insight into the effects of OCP use on exercise performance 
and will allow exercising women to make evidence-based 
decisions on OCP use within the context of sport. Moreover, 
consideration of the topic-specific methodological issues 
recommended by Cable and Elliott [82] and Elliott-Sale 
et al. [72], namely biochemical confirmation of menstrual 
phase and adequate description of OCP type, resulted in a 
further reduction in high quality studies, from 36 to 17%, 
and an increase in very low-quality studies, from 0 to 10%. 
Future studies should use appropriate biochemical out-
comes (i.e., blood samples to determine the concentration 
of endogenous oestradiol and progesterone) to confirm the 
hormonal milieu in OCP users, and naturally menstruating 
women, a tenet that is also supported by Janse de Jonge 
[83]. Such measures would permit the relationship between 
specific ovarian hormonal profiles and exercise performance 
to be established. In addition, future investigations should 
describe the type of OCP used to the level of detail required 
for categorisation or replication, as different types of OCPs 
cause varying concentrations of endogenous sex hormones, 
resulting in non-homogenous participant groups [72]. The 
heterogeneity, caused by the non-homogenous populations 
plus the considerable variation in outcomes measured, likely 
contributed to the relatively large between study variance 
observed. In the future, it would be interesting to tease out 
which factors might cause some women to have a negative 
effect, while others do not, but this was not possible with 
the current evidence base. Future studies need to include 
homogenous populations, improve methodological quality 
and limit confounders to facilitate a deeper understanding 
of individual effects.
5  Conclusion
Collectively, our results indicate that OCP use might result 
in slightly inferior exercise performance on average when 
compared to non-use, although any group level effect is 
likely to be trivial. Although most of the data used in this 
meta-analysis were rated as moderate to low quality (83% 
of the total studies), a sensitivity analysis of moderate and 
high quality papers (67% of the total studies) did not change 
the general findings described herein, thus bolstering the 
confidence in the evidence. From a practical perspective, 
as the effects tended to be trivial and variable across stud-
ies, there appears to be no performance related evidence to 
warrant general guidance on OCP use compared with non-
use. As such, an individualised approach should be taken, 
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based on each athlete’s response to OCP use, along with 
other factors such as their primary objective for using OCPs, 
and their experience of the naturally occurring menstrual 
cycle. Moreover, the difference in exercise performance 
between the OCP consumption and withdrawal phases was 
estimated on average to be close to zero, suggesting that 
the endogenous hormonal profile is the prevailing driver of 
performance rather than the supplementation of exogenous 
hormones. From a practical perspective, there appears to be 
no performance related evidence to warrant general guid-
ance on OCP consumption versus OCP withdrawal.
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